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Abstract	  
	  
Objectives	  
 
This research assesses whether structural variations can predict disease expression 
and whether gene-environment interactions can predict radiographic severity and 
progression. 
Methods 
 In	  a	  cohort	  of	  896	  AS	  patients	  the	  associations	  of	  UGT2B17	  CNV	  with	  HLA	  
B*27	  and	  extra-­‐articular	  features	  were	  compared	  using	  the	  Chi-­‐	  Squared	  test.	  
A second cohort of 76 AS patients were assessed using multiple linear regression 
analysis of serial radiographic assessments and SNPs from three genes related to smoking 
metabolism. 
Results 
 
No association was found between having UGT2B17 CNV 2 and IBD (p-value = 
0.155), psoriasis (p-value = 0.481), uveitis (p-value = 0.466) or HLA-B*27 positivity (p- 
value = 0.118). 
Two SNPs from CHRNA7 were associated with radiographic severity: rs11071593 
and rs7178176 (p-value = 0.0005). Two SNPs from CHRNA7 were associated with 
radiographic progression: rs2337506 and rs12910885 (p-value < 0.0001). 
 
Conclusion 
 
No association was found between UGT2B17 CNVs and disease expression; 
however, we have demonstrated an association between CHRNA7 SNPs and AS 
radiographic severity and progression. 
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1	  
 
Introduction	  
2	   
 
1.1 - Background of Ankylosing Spondylitis 
 
Ankylosing Spondylitis (AS) is an inflammatory disease belonging to the disease 
group spondyloarthropathies (SpA), which primarily affects the axial skeleton and 
sacroiliac joints (Edavalath, 2010). Other disease entities that belong to the SpA group are 
psoriatic arthritis (PsA), enteropathic arthritis, inflammatory bowel disease (IBD) and 
Reactive Arthrtis (ReA) (Atzeni et al., 2014). AS occurs in approximately 0.1% to 1% of 
the population and onset of disease is generally in the early to late twenties. Men are two 
to three times more likely to be affected than women. Traditionally AS has been 
diagnosed by the modified New York criteria on the basis of its primary clinical and 
radiographic characteristics: low back pain and stiffness, limitation of lumbar spine, 
limitation of chest expansion and radiographic sacroiliitis (National Institute for Health 
and Clinical Excellence Technology Appraisal Guidance, 2008). With the most recent 
classification criteria, AS now falls into a broader spectrum of chronic back pain, which is 
now referred to as axial spondyloarthritis (Rudwaleit et al., 2009). For the purpose of this 
study, we investigate AS rather than axial SpA, as this represents a homogenous subset of 
patients with axial SpA. While the pain from inflammation is often dull and persistent, it 
has the potential to be severe and disabling, primarily due to a significant loss of range of 
movement in the axial spine. 
Increased inflammation causes the ankylosis of individual vertebrae, leading to 
decreased spinal mobility and secondary diseases as syndesmophytes form in the joints 
between bordering vertebrae (Lian et al., 2013; Spondylitis Association of America, 
2013). A common phenotypic expression of the disease is a bamboo spine, an 
exaggerated concave in the thoracic spine, which results from decreased spine mobility 
	   
 
due to spinal fusion (Boonen & van der Linden, 2006). With respect to spinal 
inflammation, individuals often experience other inflammatory musculoskeletal 
manifestations, such as enthesitis and dactylitis. Enthesitis occurs when the insertion  
point of tendons and ligaments to the bone become inflamed. Common sites of enthesitis 
include insertion of Achilles tendon, costochondral and costovertebral insertions 
(Salvarani & Fries, 2009). Dactylitis is characterized by diffuse swelling of the fingers  
and toes due to inflammation of the tendon sheath around the digits. 
AS is associated with select extra-articular features. Common extra-articular 
features include acute anterior uveitis (AAU), psoriasis and IBD. AAU occurs in about 25 
to 40% of AS patients and is characterized by unilateral eye pain, blurring of vision and 
photophobia. AAU is often recurrent and must be treated immediately or else it could  
lead to permanent ocular damage. Psoriasis occurs in up to 10% of AS patients and is 
characterized by hyperproliferative scaly eruptions, particularly in the scalp, nails and 
extensor surfaces of the joints. Clinical Crohn’s disease or ulcerative colitis (UC) occurs 
in 10% of patients with AS, although sub-clinical evidence of bowel inflammation has 
been reported in up to 60% of AS patients (Salvarani & Fries, 2009). Recent studies have 
also reported an increased incidence of cardiovascular disease with AS (Haroon,  
Paterson, Li, Inman, & Haroon, 2015). Other extra-articular manifestations include apical 
pulmonary fibrosis, aortic insufficiency and osteopenia. 
Radiographic progression is considered to be an important marker for damage in 
individuals with AS (Ramiro et al., 2013). It encompasses structural changes in the spine 
and sacroiliac joints. Measurement of the degree of severity of sacroiliitis in a radiograph 
is a requirement for the diagnosis of AS by the modified New York criteria (Poddubnyy 
4	   
 &	  Sieper,	  2012).	  Radiographic	  progression	  is	  scored	  on	  the	  modified	  Stoke	  Ankylosing	  Spondylitis	  Spine	  Score	  (mSASSS;	  Poddubnyy	  &	  Sieper,	  2012).	  The	  most	  substantial	  amount	   of	   radiographic	   progression	   is	   observed	   in	   the	   first	   10	   years	   after	   disease	  onset	   (Lian	   et	   al.,	   2013).	   mSASSS	   is	   the	   tool	   used	   for	   measuring	   radiographic	  progression,	   one	   of	   the	   core	   outcomes	   for	   AS.	   The	   interobserver	   reliability,	   truth,	  discrimination	   and	   feasibility	   of	  modified	   Stoke	  Ankylosing	   Spondylitis	   Spine	   Score	  (mSASSS)	   was	   assessed	   in	   AS	   over	   a	   3	   year	   period	   (Salaffi	   et	   al.,	   2007).	   This	   was	  compared	   to	   the	  Bath	  Ankylosing	  Spondylitis	  Radiology	   Index-­‐-­‐spine	  (BASRI-­‐spine).	  Interobserver	   agreement	   was	   analyzed	   by	   intraclass	   correlation	   coefficients	   (ICC).	  The	   BASRI-­‐spine	   reached	   intra-­‐	   and	   interobserver	   ICC	   of	   0.755	   and	   0.831,	  respectively.	   The	  mSASSS	   scores	   were	  more	   reliable,	   with	   ICC	   of	   0.874	   and	   0.941,	  respectively.	   With	   regards	   to	   sensitivity	   to	   change,	   it	   was	   found	   that	   mSASSS	  classified	  the	  highest	  percentage	  of	  patients	  with	  more	  changes	  than	  the	  BASRI-­‐spine	  (mSASSS:	   35.8%	   vs.	   BASRI-­‐spine:	   15.8%).	   Thus	   mSASSS	   offers	   advantages	   in	  measurement	   properties	   and	   is	   the	   most	   appropriate	   method	   by	   which	   to	   assess	  progression	  of	  structural	  damage	  in	  AS.	  
The condition is initially treated with anti-inflammatory medications, particularly non-
steroidal anti-inflammatory drugs (NSAIDs), although some patients with AS are able to 
manage their condition without any pharmacological agents. For those AS patients 
receiving NSAIDs, about 70 to 80% report a significant benefit. There is no convincing 
evidence that the class of NSAID makes a significant difference, although the maximum 
dose of any particular NSAID is required. At present, there is controversy about the use of 
continuous versus on demand NSAID therapy. Earlier reports suggested that continuous 
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NSAIDs might delay radiographic progression; however, more recent studies have not 
reported this benefit (Sieper et al., 2015). Continuous NSAIDs are also associated with 
more adverse events, particularly gastroduodenal ulcers, ischemic heart disease and renal 
toxicity. Traditional disease-modifying antirheumatic drugs (DMARDs) are not used to 
treat axial symptoms, although selected DMARDs, such as sulfasalazine, may be used for 
peripheral arthritis. Biologic agents, particularly anti-tumor necrosis factor (TNF) agents, 
are increasingly being used in treatment regimes. Anti-TNF agents have demonstrated 
significant benefit in reducing pain and stiffness as well as in enhancing mobility and 
overall quality of life. These medications have also demonstrated reduction in spinal 
inflammation and possibly decreased radiographic progression with early and prolonged 
use. More recently, interleukin (IL)-17 inhibition has demonstrated efficacy in AS 
treatment (Baeten et al., 2015). Management throughout the course of AS can also include 
exercise, stretching and physical therapy (Spondylitis Association of America, 2013). 
1.2 - Genetic Analysis Studies 
 
The etiology of AS remains unknown, but it likely results from interplay 
between genetic, immunological and environmental factors. Multiple lines of 
evidence support a genetic basis of AS. Evidence for a genetic basis of AS is derived 
from family based investigations, association studies with human leukocyte antigens 
(HLA) and mounting evidence from genome-wide association studies (GWAS). 
 
1.1.1 - Heritability of AS 
 
Large epidemiological studies have estimated the sibling recurrence risk ratio 
in AS to be greater than 52, while the index of heritability for AS is greater than 90% 
(Brown et al., 1997; Brown, 2008; Brown, 2011). There is substantial evidence 
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through twin studies that have demonstrated that disease susceptibility is largely due 
to a genetic component (Brown et al., 1997; Reveille, 2011). Studies comparing 
monozygotic and dizygotic twins have confirmed that AS is a familial disease 
(Breban, 2006; Brown, 2008). AS twin studies have consistently reported 
significantly higher correlations of the disease between monozygotic twins compared 
with dizygotic twins, with coherence rates of 50 to 75% and 12.5 to 15%, 
respectively (Breban, 2006; Brown, Crane & Wordsworth, 2002; Jarvinen, 1995). 
Clinical manifestations of AS, in particular age of onset and disease outcomes 
(including disease activity and function), were also noted to be heritable. 
1.1.2 - Genetic Studies 
 
1.2.2a	  Linkage	  Studies	  
 
Linkage Mapping of genetic variants within families occurs when a gene at a 
particular locus segregates dependent on another gene at a neighboring locus on the 
same chromosome (Sims, Wordsworth & Brown, 2004). Linkage studies are 
particularly helpful in identifying genetic variants with large effect sizes when a 
complex disease segregates in a Mendelian inheritance. 
To date, three large genome-wide linkage studies have been implemented in 
AS populations. All three studies suggested strong linkage in the major 
histocompatibility complex (MHC) chromosomal regions. Additionally, these studies 
implicate regions outside of the MHC genes. An assessment of an AS population in 
the United Kingdom, defined by the modified New York criteria, found significant 
linkage in chromosome 16q and suggestive linkage in chromosomes 2q, 9q, 10q and 
19q (Laval et al., 2001). A study of North American sibling pairs found suggestive 
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linkage in chromosomes 6q and 11q (Zhang et al., 2004). The patients in this 
population were also defined by the modified New York criteria for AS. The third 
study, a French AS population analysis defined by the European 
Spondyloarthropathy Study Group, found suggestive linkage in chromosomes 5q, 9q, 
13q and 17q (Groupe Français d'Etude Génétique des Spondylarthropathies, 2004). 
When the data from these three linkage studies were combined the results attest to 
suggestive linkage in chromosomes 10q and 16q and nominal linkage in 
chromosomes 1q, 3q, 5q, 6q, 9q, 17q and 19q (Chandran & Rahman, 2010). Despite 
the initial enthusiasm related to genome-wide linkage studies, very few 
robust candidate genes have been identified using this approach. Thus genome-wide 
linkage studies have largely been abandoned. 
 
1.2.2b	  Genome-­‐Wide	  Association	  Studies	  
 
GWAS are used for identifying the risk alleles of small effect sizes. These 
studies identify genetic variants that occur in high frequencies in affected versus 
unaffected individuals across the human genome (Patnala, Clements & Batra, 2013). 
Linkage Disequilibrium (LD) mapping has greatly facilitated the GWAS approach 
(Morota, Valente, Rosa, Weigel & Gianola, 2012). LD blocks are regions of 
chromosomes containing genetic loci that segregate and are inherited together. 
Four GWA studies have been performed in AS populations to date (Brown, 
2011; IGAS, 2013; Pointon et al., 2010a; Pointon et al., 2010b; TASC, 2010; TASC 
& WTCCC2, 2007). The first three GWAS identified 12 loci relating to the disease 
beyond the well-established association of HLA-B*27 to AS disease susceptibility 
(Brown, 2011). A recent GWA study in June 2013, by the International Genetics of 
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Ankylosing Spondylitis (IGAS) Consortium, identified 13 new genetic loci 
associated with disease in AS patients. To date, there are 37 genes that have reached 
genome-wide significance in AS (Table 1-1). With the addition of this latest GWAS, 
24.4% of the heritability of AS is genetically described. Of the 24.4%, 20.1% is 
explained by HLA-B*27 and 4.3% is explained by the additional 25 loci (IGAS, 
2013). Even with the identification of 25 new loci associations, there is still a large 
portion of AS heritability that is undetermined. 
The identification of 13 new gene loci and the verification of 12 previously 
identified gene loci in the GWA study by IGAS (2013) gives preference to four 
biological pathways in the explanation of AS pathogenesis. First, among the loci 
identified are the IL-23 pathway genes, suggesting that the IL-23 pro-inflammatory 
pathway is involved in disease presentation in AS patients. In the second case, some 
loci identified are aminopeptidase genes suggesting that pathways involved in gut 
immunity are possibly linked to pathways involved in AS pathogenesis. Thirdly, 
pathways involved in T cell lymphocyte activation and differentiation are implicated. 
IGAS (2013) found an association between the single nucleotide polymorphisms 
(SNPs) implicated in AS and the cell counts of both CD8+  and CD4+  T cell 
lymphocytes. This further suggests that lymphocyte activation pathways play a role 
in AS disease pathogenesis. Lastly, the pathways involved in peptide signaling before 
HLA class I presentation are implicated (IGAS, 2013). These hypotheses of AS 
pathogenesis are explained in greater detail below in reference to the specific genetic 
loci to which they pertain. 
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1.3 - Review of Major AS Genes 
 
 
1.3.1 - Immunogenetics 
 
 
 
1.3.1a	  -­‐	  HLA-­‐B*27	  
 
Of individuals affected by AS, approximately 80% are HLA-B*27 positive. 
Only 1 to 5% of HLA-B*27 positive individuals have AS, leaving a large amount of 
the heritability of AS unexplained by this gene (Reveille, 2011; Reveille, 2012; van 
der Linden, Valkenburg, de Jongh & Cats, 1984). HLA-B*27, a MHC class I 
molecule, accounts for approximately 20.1% of the heritability of AS (IGAS, 2013). 
This gene is located on the short arm of chromosome 6 and codes for four major 
proteins that are associated with AS, each varying in portion among different 
ethnicities. The most abundant protein in Western European Caucasian individuals is 
HLA-B*27:05, the parent allele, which comprises approximately 90% of the 
variants within this ethnicity. The remaining 10% of HLA-B*27 variations in 
Western European Caucasian individuals is within HLA-B*27:02. The two other 
primary variants, HLA-B*27:07 and HLA-B*27:04, are found mainly in Southern 
Asia and Eastern Asia, respectively. Of the 69 identified subtypes of HLA-B*27, 
these four are found most often in populations. The remaining subtypes are 
considered rare and are generally identified only in families (Reveille, 2011). Three 
hypotheses explain the role of  HLA-B*27  in  mediating  vertebral   joint 
inflammation in AS. The first hypothesis suggests that CD8+  T cell receptors 
recognizeHLA-B*27. A cytotoxic T cell autoimmune response is initiated by a 
receptor on CD8+ T cells that identifies its arthrotigenic peptide, HLA-B*27 (Reveille, 
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2011; Salvarani & Fries, 2009). The second hypothesis suggests that the heavy chain 
of HLA-B*27 misfolds, or homodimerizes, while in the endoplasmic reticulum (ER) 
causing stress by activating an unfolded protein response. The Cys67 residue on the α1 
domain of the heavy chains causes HLA-B*27 to homodimerize, or misfold, which 
inhibits transcription and translation. The homodimerized domain directs BiP, the ER 
chaperone, eliciting downstream inflammation. The last hypothesis is that tissue-
specific homing cells of the inflammatory response in the gut epithelium are 
inappropriately rerouted to synovial compartments, therefore moving from the gut into 
the joints (Fantini, Pallone & Monteleone, 2009; Reveille, 2011; Salvarani & Fries, 
2009). Interestingly, this particular hypothesis supports mechanisms that guide genetic 
overlap between AS and IBD. 
MHC genes other than HLA-B*27 have been implicated in AS susceptibility. 
The most notable non-B*27 genes identified have been HLA-B*40 and HLA-B*60 
(Reveille, 2014). Inconsistent associations have been noted for non-MHC genes, 
including MIC-A genes as well as TAP, low molecular weight proteosome (LMP) 
and TNF alleles. 
1.3.2 - Gene Variants Identified via GWAS 
 
The candidate genes in this study were selected on the basis of the following 
rationale. Firstly, genes reaching genome wide significance in multiple GWAS 
studies were preferred as we were wondering whether established genes is related to 
radiographic disease severity and function. Secondly, genes reaching statistical 
significance on previous candidate gene studies for radiographic severity were ideal 
for inspection. Lastly, high priority functional candidates that were related to new 
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bone formation, but not necessarily shown to be associated with AS, were chosen.  
We were suggesting that these genes are only relevant for disease expression and not 
susceptibility. 
GWA studies have been instrumental in identifying multiple candidate genes that 
have reached genome-wide significance. These genes include IL-23R, RUNX3, IL-1 
region  and  IL-1R2,  ANTXR2,  IL-12,  CARD9,  PTGER4,  KIF21B,  STAT3,    
intergenic 
regions, TNF pathway associated genes, ERAP1, TYK2, IL-6, IL-27, EOMES, ZMIZ1, 
IL7R, BACH2, SH2B3, GPR35, GPR37, GPR65, GPR25 and HLA-A*0201 
(Appendix   1; 
Brown, 2011; IGAS, 2013; Reveille, 2012). IL-23R and intergenic regions were 
associated with AS in both HLA-B*27 positive and negative patients, confirming that 
the association of these genes was not the result of gene-gene interaction but simply a 
genetic component independently associated with the disease. 
1.3.2a	  -­‐	  IL-­‐23R	  
The IL-17/IL-23R axis has been identified as having a significant role in AS, 
IBD and psoriasis susceptibility (De Vos, Hindryckx & Laukens, 2011; Robinson & 
Brown, 2012). One SNP, rs11209026, is common to all three diseases. IL-23R 
accounts for approximately 0.31% of the heritability of AS (Brown, 2011; Reveille, 
2012). IL-23R regulates a downstream inflammatory response by initiating the 
differentiation of CD4+ T cells into Th-17 helper (Th17) cells. The Th-17 cells 
produce IL-17, a    pro-inflammatory 
 
cytokine, which stimulates fibroblasts, epithelial cells and macrophages to induce 
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inflammation through the production of pro-inflammatory mediators: IL-1, IL-6, 
TNF-α, NOS-2, metalloproteases and chemokines (De Vos et al., 2011; Iwakura & 
Ishigame, 2006; Matzkies et al., 2012; Reveille, 2012; TASC, 2010). 
 
1.3.2b	  -­‐	  IL-­‐12B	  
IL12B, at chromosome 5q33, accounts for approximately 0.11% of AS 
heritability (Brown, 2011; Reveille, 2012). The protein encoded by this gene, 
IL12B40, has a p40 subunit and is shared by both the IL-12 and IL-23 pathways 
(Wong et al., 2012). The product binds IL-23R (Apel et al., 2013). The IL-12 product, 
in addition to binding IL- 23R, plays a role in the Th-17 signaling pathway by 
overseeing CD4+ T cell  differentiation into Th-17 cells. The presence of Th-17 cells 
initiates cytokine production leading to the assemblage of pro-inflammatory factors. 
This pathway is involved in IBD and PsA pathogenesis; an association between the 
diseases and IL-12B has been reported (Jadon et al., 2013; Matzkies et al., 2012; 
Reveille, 2012; Ruutu et al., 2012). Again, the genetic overlap between the three 
inflammatory diseases, AS, IBD and PsA, suggests a contribution to disease 
susceptibility. 
 
1.3.2c	  -­‐	  ERAP1	  
 
The endoplasmic reticulum aminopeptidase 1 (ERAP1) gene encodes an 
aminopeptidase linked to the ER and trims peptides in preparation for binding MHC 
class I molecules. It is responsible for approximately 0.34% of the heritability of AS 
(Brown, 2012; Reveille, 2012). ERAP1 was only found to be associated with AS in 
HLA-B*27 positive patients (Reveille, 2011; Robinson & Brown, 2012). 
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1.3.2d	  -­‐	  CARD9	  
 
The product of CARD9 expression is caspase recruitment domain-containing 
protein 9 (hCARD9), which is responsible for signaling production of TNF, IL-6 and 
IL-23. hCARD9 uses NFκB to induce production of TNF, IL-6 and IL-23 while also 
differentiating T cells into Th-17 cells, which produce IL-17 and IL-23. The SNPs of 
CARD9 were found to be relatively strongly associated with AS while still only 
accounting for 0.034% of the heritability of the disease (Brown, 2011; Reveille, 
2012). CARD9 was also associated with PsA and IBD. The high frequency of 
common genetic factors between the three inflammatory diseases supports the role of 
CARD9 in AS susceptibility (Ruutu et al., 2012; TASC & WTCCC2, 2011). 
 
 
1.3.2e	  -­‐	  STAT3	  
 
Signal transducer and activator of transcription 3 (STAT3) was found to be 
associated with AS susceptibility. It codes for a molecule involved in the IL-17/IL-23 
signaling pathway, which is an inflammatory response (Reveille, 2011; Reveille, 
2012). STAT3 mediates the signal of IL-22 and IL-23 to the target cells, lymphoid 
cells and epithelial cells (Ciccia et al., 2012). The activated gene product is 
phosphorylated due to the binding of IL-23 to IL-23R (Di Meglio et al., 2011). The 
activation of the STAT3 product elicits IL-23 expression, rendering an autoimmune 
inflammatory response. In individuals with AS and Crohn’s disease, IL-22 and IL-23 
expression was upregulated, resulting in the subsequent over-expression of STAT3 in 
the ileum of the small intestine. STAT3 has a genetic overlap with other autoimmune 
diseases such as Crohn’s disease and type 1 diabetes (TASC & SPARCC, 2010). 
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1.3.2f	  -­‐	  TYK2	  
 
Tyrosine kinase 2 (TYK2) is involved in intercellular signaling in the IL-23 
pathway through signal transduction from IL-23R and other cytokine receptors. A 
common genetic variant (rs35164067) has been associated with AS and Crohn’s 
disease. Meanwhile another variant in TYK2 (rs6511701) is associated only with AS 
and not Crohn’s disease (IGAS, 2013). 
 
 
1.3.2g	  -­‐	  RUNX3	  
 
RUNX3 is located on chromosome 1p36 and is responsible for about 0.12% of 
AS heritability (Brown, 2011; Reveille, 2012). It encodes a transcription factor 
involved in differentiation of CD8+ T cells, which suggests that RUNX3 may affect 
HLA-B*27. HLA class I molecules, such as HLA*B27, present antigens to CD8+ T 
lymphocytes (Reveille, 2012). CD8+ T cell molecules recognize the HLA-B*27 
receptors eliciting an immune response with cytotoxic T cells. RUNX3 has also been 
demonstrated to be involved in PsA susceptibility, with an effect size similar to that 
found in AS. Considering the known genetic overlap between the two inflammatory 
diseases, the additional observation on the co-familial genetic nature of the RUNX3 
gene in both PsA and AS supports the involvement of the gene in AS heritability 
(Apel et al., 2013). 
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1.3.2h	  -­‐	  IL-­‐6	  
 
IL-6 promotes naïve T cells to differentiate to Th-17 cells. The exact 
mechanism in which IL-6R exerts an effect is unclear. IL-6R functions 
simultaneously with transforming growth factor-β. This combination of factors also 
mediates the inhibition of transforming growth factor-β directed differentiation to 
Treg cells (IGAS, 2013). 
 
 
1.3.2i	  -­‐	  IL-­‐27	  
 
IL-27 affects the IL-23 pathway by promoting the differentiation of CD4+  T  
cells. 
 
This gene suppresses the differentiation of Th-2 and Th-17 cells (IGAS, 2013). 
 
 
 
Table 1-1: Genes found to be significantly associated with AS through SNP-based 
GWA 
 
studies 	  
Nearby Gene(s) SNP Odds Ratio 
 
IL-23R 
 
rs11209026 
 
1.90 
LTBR-TNFRSF1A rs11616188 1.38 
2p15 rs10865331 1.36 
ERAP1 rs30187 1.35 
KIF21B rs2297909 1.25 
21q22 rs378108 1.25 
TBKBP1 rs8070463 1.24 
ANTXR2 rs4389526 1.21 
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PTGER4 rs10440635 1.20 
 
RUNX3 rs11249215 1.19 
IL-12B rs6556416 1.18 
CARD9 rs10781500 1.18 
IL-1R2 rs2310173 1.18 
IL-6R rs4129267 1.14 
FCGR2A rs1801274 1.11 
UBE2E3 rs12615545 1.12 
GPR35 rs4676410 1.13 
BACH2 rs17765610 1.15 
ZMIZ1 rs1250550 1.11 
NKX2-3 rs11190133 1.15 
SH2B3 rs11065898 1.11 
GPR65 rs11624293 1.20 
IL-27-SULT1A1 imm_16_ 28525386 1.11 
NOS2 rs2531875 1.12 
TYK2 rs35164067 1.14 
ICOSLG rs7282490 1.11 
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1.3.3 - Missing Heritability 
 
The addition of 25 more genetic associations with the disease adds little to 
the heritability of AS, where only an extra 4.3% of the genetic variance is explained. 
The total heritability of AS identified to date is 24.4%, suggesting that other genetic 
variations such as structural variations, epigenetics and rare variants along with 
complexities of genetic interactions (gene-gene interactions and gene-environment 
interactions), could explain some of the missing heritability (IGAS, 2013; Reveille, 
2012). 
 
 
1.3.3a	  -­‐	  Copy	  Number	  Variations	  
 
Copy number variations (CNV) are structural variants in the genes that 
involve duplications or deletions of large regions of deoxyribonucleic acid (DNA). 
The previously discussed 24.4% of genetic heritability of AS has been explained 
through SNP-based GWAS. There is a large amount of unexplained genetic 
heritability that could be elucidated through an alternative method of genetic 
analysis. There is evidence to support CNV analysis in AS as an effective means for 
determining genetic heritability. In 2014, Jung et al. were the first to identify an AS-
associated CNV variant in a Korean population using a SurePrint G3 Human CNV 
180K microarray. The study found that 227 CNV regions were associated with AS. 
Of the candidate genes that were examined through the CNV GWA study and 
independent replications, 9 were successfully replicated in the analysis: 1q32.2 
(HHAT), 1p34.2 (BMP8A), 2q31.2 (PRKRA), 6p21.32 (HLA-DPB1), 11q22.1  
(CNTN5),  13q13.1  (EEF1DP3),  14q24.2  (RGS6),  16p13.3 and 
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22q11.1 (IL17RA; Table 1-2). The 5 deletion-type CNV regions, in 1q32.2, 2q31.2, 
6p21.32, 13q13.1 and 16p13.3, were associated with an increased risk of AS. The 
other 4 CNV regions were protective. Of the 9 genes that were found to be significant 
in the first replication set, 4 CNV regions in 1q32.2, 2q31.2, 6p21.32 and 16p13.3 
were consistently significantly replicated (Jung et al., 2014). This study was the first 
to explore CNV based GWAS to explain the pathogenesis of AS. 
 
A recent study of a multiplex family identified that the UDP- 
glucuronosyltransferase 2 polypeptide B17 (UGT2B17) gene is present in copy 
number 2 in individuals affected by AS (Uddin, Sturge, Peddle, O'Rielly & Rahman, 
2013). UGT2B17 is a functional gene associated with androgen metabolism. This 
gene is responsible for glucoronidation of testosterone (Ekstrom et al., 2013). Given 
that glucuronidation is an important step in the metabolism of nicotine, the UGT2B17 
gene likely plays a role in the pathway of nicotine metabolism (Chen et al., 2010). 
With the identified association between AS and UGT2B17 in a multiplex family, and 
given the role of UGT2B17 in nicotine metabolism, we are postulating that UGT2B17 
may influence radiographic progression or disease severity in AS through a gene-
environment interaction. 
UGT2B17 is a gene that codes for an enzyme belonging to the UDP- 
glucuronosyltransferase family. It is a part of the UGT2B subfamily, which is 
primarily found in the hepatocytes and extrahepatic tissues involved in androgen 
metabolism (Turgeon, Carrier, Levesque, Hum & Belanger, 2010). It metabolizes 
steroid hormones by catalyzing the binding of the 17β-hydroxyl position of 
dihydrotestosterone, testosterone and 3α-diol to the gene product, which 
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glucuronidates androsterone (Pâquet et al., 2012). UGT2B17, therefore, has a role in 
the formation of estrogen, a hormone affecting bone structure and strength. The 
UGT2B17 gene dosage, corresponding to CNV, affects the concentration of androgen 
metabolites produced and results in varying amounts of bone formation (Angstadt et 
al., 2013; Conrad et al., 2010). The CNV of UGT2B17 has been found to have an 
influence on bone mineral density, cortical thickness and buckling ratio (Giroux, 
Bussieres, Bureau & Rousseau, 2012; Yang et al., 2008). 
Enhanced expression of the gene affects bone formation, increasing the risk of 
osteoporosis. AS is characterized by the formation of new bone in the vertebral 
column; yet, osteoporosis is a common pathogenic characteristic of the disease, 
which increases the risk of spinal fracture (Yang et al., 2008). The role of the 
UGT2B17 gene CNV in bone formation and thickness provides the basis for further 
investigation of CNV analysis in individuals with AS in this study. 
Expression of UGT2B17 and UGT2B10 produces enzymes that catalyze the 
N- glucouronidation pathways of nicotine metabolism. Both genes, belonging to the 
UDP- glucuronosyltransferase family, are polymorphic. UGT2B17, along with 
UGT2B10, is involved in the metabolism of nicotine by initiating the glucuronidation 
of 4- (methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), a major metabolite from 
the nicotine-derived tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-
pyridyl)-1- butanone (NNK). UGT2B17 deletion significantly lowers the 
glucoronidation activity in smokers. The gene catalyzes the phase II detoxification 
process for nicotine to cotinine to trans-3’-hydroxycotinine (3HC; Chen et al., 2010; 
Chen, Giambrone & Lazarus, 2012). Radiographic progression in individuals with 
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AS has been demonstrated to occur faster in patients who smoke as compared to non-
smokers. The previously found relationship between the UGT2B17 gene and AS, in 
combination with the role of UGT enzymes in nicotine metabolism, warrants further 
investigation of UGT2B17 CNV, smoking status and AS disease outcomes. 
Table 1-2: Genes found to be significantly associated with AS through CNV-
based GWAS 
 
Gene Chromosome 
 
HHAT	   1q32.2*	  
BMP8A	   1p34.2	  
PRKRA	   2q31.2*	  
BMP6	   6p24.3	  
HLA-­‐DPB1	   6p21.32*	  
CNTN5	   11q22.1	  
EEF1DP3	   13q13.1	  
RGS6	   14q24.2	  
-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐	   16p13.3*	  
IL17RA	   22q11.1	  
 
 
 
1.3.3b	  -­‐	  Gene-­‐Gene	  Interactions	  
 
The remaining genetic variability may be attributed to multiple gene-gene 
interactions. For example, the gene-gene interaction between HLA-B*27 and ERAP1 
contributes to disease progression in AS patients. ERAP1 was only associated with 
the disease in individuals who were HLA-B*27 positive, thus confirming that it is 
this interaction that elicits disease susceptibility and not the genetic contribution of 
ERAP1 alone (TASC & WTCCC2, 2011; Reveille, 2011; Reveille, 2012). That 
ERAP1 is associated with AS susceptibility only in the presence of HLA-B*27 
suggests that AS predisposition does not always stem from the presence of HLA-
B*27 alone. A malfunctioning ERAP1 leads to misfolding of the HLA-B*27 heavy 
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chain, which causes stress by activating an unfolded protein response that inhibits 
appropriate transcription and translation. When compared with controls, individuals 
with AS have overexpressed ERAP1 within dendritic cells, resulting in loss of 
optimal regulation of the gene product (TASC & WTCCC2, 2011). Gene-gene 
interaction has also been noted between ERAP1 and HLA-B*40 in AS, HLA-B*51 in 
Bechet’s disease and HLA-Cw6 in psoriasis. This suggests that the interaction of 
ERAP-1 and HLA genes is very important in the pathogenesis of these disorders, as 
there are very few instances where gene-gene interaction has been noted for a 
complex disease (Brown, Kenna, & Wordsworth, 2015). 
 
 
1.3.3c	  -­‐	  Gene-­‐Environment	  Interaction:	  Smoking	  and	  AS	  
 
Associations between environmental factors and disease outcomes have been 
observed in PsA patients. Smoking has been linked to worsening disease outcomes in 
PsA individuals, making smoking a prognostic factor for PsA (Duffin et al., 2009; 
Tillett et al., 2013). The IL-13 region has been identified as being associated with 
increased susceptibility of PsA in psoriasis patients. Interestingly, smoking is 
protective in psoriasis patients, delaying the onset of PsA, especially in those patients 
with IL-13 polymorphisms. AS and PsA are co-familial diseases, being included in 
the spondyloarthropathy family and overlap genetically (Dougados & Baeten, 2011). 
The genetic similarities between AS and PsA warrant investigation of the effect of 
smoking on AS disease outcomes. An interaction between the environment and 
genetic factors of AS may contribute to the missing genetic heritability. 
AS disease activity and radiographic progression have been observed to be 
22	   
significantly worsened and occur more rapidly in affected individuals who smoke 
(Kaan & Ferda, 2005; Mattey, Dawson, Healey & Packham, 2011; Poddubnyy et al., 
2012, Ward et al., 2009). A gene-environment interaction exists between smoking 
and bone metabolism in osteoblast cells  (Rothem,  Rothem,  Soudry,  Dahan  &  
Eliakim,  2009). Spinal bone formation is a characteristic feature in AS. Median 
disease scores on standardized disease functioning, pain and quality of life 
questionnaires for AS patients have been found to be significantly higher in 
individuals who smoked as compared to those who never smoked (Averns et al., 
1996; Chung, Machado, van der Heijde, D'Agostino & Dougados, 2012). An 
additional dose-dependent relationship between pack years and disease worsening 
was also established (Mattey et al., 2011). Smoking has been found to be associated 
with spinal radiographic progression in individuals with early stage SpA and, 
furthermore, smoking status was positively associated with mSASS scores (Chung et 
al., 2012; Poddubnyy et al., 2012). Evidence suggests that smoking status alters the 
disease outcomes of AS; however, no association has been made between smoking 
and HLA-B*27 positivity. Another genetic component may thus be the factor that 
interacts with the nicotine metabolism pathways that result in poor disease outcomes. 
 
 
1.3.3d	   -­‐	   Genetics	   of	  Disease	  Expression:	  Genetic	  Association	  With	  Extra-­‐Articular	  
Features	  
Overlap in genes and inflammatory pathways occurs in comorbid diseases 
such that individuals affected by AS exhibit a number of extra-articular features like 
IBD, psoriasis and uveitis (Boone & van der Linden, 2006; Rosenbaum & Chandran, 
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2012). There are a number of genetic irregularities associated with AS, IBD, psoriasis 
and uveitis. An example of such an overlap is seen in the upregulation of the IL-
17/IL-23R pathway. This suggests that the remaining genetic heritability in AS may 
be co-familial (Brown, 2009; Reveille, 2012).   That   IBD, psoriasis   and   uveitis   
are common comorbidities associated with AS suggests that the four diseases share 
common genetic components, often causing them to occur in succession. 
IBD is an inflammation of the gastrointestinal tract. The autoimmune disorder 
encompasses two major disease classifications: Crohn’s disease and UC (Lees, 
Barrett, Parkes & Satsangi, 2011). IBD occurs in approximately 5 to 10% of all AS 
patients (Matzkies et al., 2012; Rosenbaum & Chandran, 2012). The two diseases 
share common inflammatory pathways that cause IBD to occur in combination with 
AS (Fantini, Pallone, & Monteleone, 2009). One of these pathways involves the Th-
17 cell inflammatory response, which was observed to be a common pathogenic 
mechanism in both IBD and AS (Salvarani & Fries, 2009). The genetic component 
IL-23R plays a role  in the signaling pathway involving Th-17 cells (Brown, 2009). 
The IL-23R gene is commonly mutated in protective and risk variants in both IBD 
and AS cases, adding evidence that inflammatory mechanisms for both disorders are 
similar (Lees et al., 2011). Genetic overlap between Crohn’s disease and AS has also 
been identified using GWAS at loci IL-23R, STAT3, IL-12B and TNFSF15 as well as 
the intergenic region at chr1q32. In addition to IL-23R, STAT3 and IL-12p40 play a 
role in the Th-17 inflammatory pathway (Matzkies et al., 2012). 
Uveitis, or iritis, is an inflammation of the uvea, the middle layer of the eye. It 
causes pain, watering and redness in the eye, leading to blurred vision and sensitivity 
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to light (Spondylitis Association of America, 2013). AAU occurs in 40% of patients 
with AS (Reveille, 2011). The genetic overlap between AS and uveitis is primarily 
from the strong association of both diseases with the HLA-B*27 gene. Uveitis is 
significantly associated with cervical spinal pain and HLA-B*27 positivity (De Vos et 
al., 2011). It has been observed that over 90% of individuals with AAU due to HLA-
B*27 positivity also have SpA (Reveille, 2011). It has been suggested that the 
partnership between AS and uveitis is heavily influenced by environmental factors 
(Wendling et al., 2012). 
Psoriasis is an autoimmune disorder in which thick white or red patches form 
on the skin of affected individuals. Psoriasis occurs in 20% of all individuals with 
SpA (De Vos et al., 2011). The primary genetic marker indicative of psoriasis 
susceptibility has been previously identified as HLA-C*06:02. This genetic 
component of psoriasis does not overlap with those genes identified as being 
associated with AS susceptibility; however, similar to AS, the primary genetic 
component of psoriasis appears to have an interactive relationship with ERAP1. HLA-
C*06:02 appears to be involved in a gene-gene interaction with ERAP1 in affected 
individuals in a similar fashion to the interaction between HLA- B*27 and ERAP1 in 
individuals with AS. HLA-C*06:02 and HLA-B*27 are both peptides coded from 
genes found in MHC regions. The genetic similarities between AS and psoriasis in 
this instance further support misfolding of MHC peptides as a likely explanation of 
SpA susceptibility. Furthermore, other genetic overlap exists between AS and 
psoriasis beyond the ERAP1 and MHC peptide relationship. Both diseases express 
IL-23R induction of Th-17 cells. The production of differentiated Th-17 cells results 
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in the assemblage of IL-17, an inflammatory response regulator (Iwakura & 
Ishigame, 2006; Reveille, 2012). The IL-23R gene may be a common mediator in the 
induction of inflammatory responses in AS, IBD and psoriasis. 
 
1.3.3e	  -­‐	  Rare	  Variants	  
 
The common variants identified via GWA studies marginally contribute to 
AS susceptibility. The common variant hypothesis dictates that multiple common 
variants of small effect size account for the heritability of common disease. GWA 
studies overlook rare variants as the SNPs chosen usually have minor allele 
frequency of over 1%. Additionally, linkage studies are grossly underpowered to 
identify genetic variants with low relative risk. With the advent of next generation 
sequencing, it is now possible to interrogate the genome for rare variants. These 
variants occur infrequently; however, when present, there is a large effect size. To 
date, there has only been one study performed to identify rare variants in AS patients 
(O’Rielly et al., 2015). Two familial deletions in SEC16A and MAMDC4 correspond 
with increased susceptibility to axial Spondyloarthritis (AxSpA) in HLA-B*27 
positive patients belonging to a multigenerational family. 
 
1.4 - Relevance of Research 
 
The course of AS is extremely variable: some patients only have spinal 
involvement while others have peripheral arthritis, peri-articular disease (enthestis 
and dactylitis) or extra-articular manifestations (uveitis, psoriasis, IBD). The range of 
spinal ankylosis is also quite large with some individuals having long standing 
disease with no radiographic progression while others demonstrate rapid onset of 
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spinal ankylosis over just a few years. Since these patients are young at disease onset, 
the lifelong impact of the progression is significant.  Early identification of extra-
articular features or disease 
 
progression, coupled with appropriate management, may improve the quality of life 
and prevent disability. 
At present, when a patient with SpA presents to the physician, it is not clear 
what path their disease will take. It is possible to have a mild disease, which does not 
result in deformity, or a rapidly progressive course that results in considerable 
damage. Our proposed research will identify markers for disease expression, severity 
and progression. Clinicians may be able to utilize this work to determine the future 
course of the disease at onset. That, in turn, will allow individualized treatment such 
that patients destined to have mild disease do not get aggressive treatment exposing 
them to untoward side effects, while patients with a severe pattern will be treated 
early with appropriate medications to prevent progression of damage. Modification of 
the natural history of disease is possible if an environmental factor is shown to be 
associated with worsening disease outcomes. 
 
1.4.1 - Study Objectives 
 
The proposed research will help assess whether structural variations (i.e. 
CNVs) can predict disease expression and whether gene-environment interactions 
can predict radiographic severity and progression of AS. This study has two parts:  
Part	  1:	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To	  assess	  the	  genetics	  of	  disease	  expression	  using	  recently	  identified	  CNVs	  for	  extra-­‐	  articular	  manifestations	  of	  AS;	  
Part 2:  
 
A. To assess the genetics of radiographic severity in AS using selected 
smoking related genetic variants; and 
B. To assess the genetics of radiographic progression in AS using selected 
smoking related genetic variants. 	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2	  
 
Materials	  and	  
Method
	   
 
2.1 - Ethical/Administrative Approval 
 
This project fell under the broader study of Genetics of AS and was approved by 
the Health Research Ethics Authority (Ref. #99.172). Ethics approval was renewed 
annually. Permission was given by the University Health Network of the Toronto  
Western Hospital and the University of Alberta for use of the clinical information and 
laboratory results of their AS patients. Each of these centers also has approval from their 
respective ethics committees. A material transfer agreement has been in place between 
these universities and Memorial University for over a decade. The clinical information 
was extracted from The Spondyloarthritis Research Consortium of Canada (SPARCC) 
database. In each center, informed consent was obtained from all patients used in the 
study prior to their information being recorded in the database. 
 
 
2.2 - Study Design 
 
This is a retrospective case study. Patient data was previously collected by the 
SPARCC consortium. For the purpose of this study, AS cases were stratified based on 
extra-articular manifestations, radiographic severity or radiographic progression. 
 
 
2.3 - AS Patient Ascertainment 
 
 
 
2.3.1 - Location 
 
The patients used in this study were recruited from three large AS cohorts located 
in Newfoundland, Toronto and Alberta. All genetic and statistical analysis was 
performed at Memorial University. 
	   
 
2.3.2 - Diagnostic Criteria 
 
All AS patients satisfied the modified New York criteria (Table 2-1). One of 
three clinical criteria must be satisfied in combination with one radiological criteria for 
full diagnosis of AS. The first clinical requirement is that the individual must have 
experienced low back pain and stiffness that improves with exercise but is not relieved 
by rest for more than three months. The second clinical qualification states that the 
individual has limitation of the lumbar spine in both the sagittal and frontal planes. The 
third criterion requires that  the individual have limitation of chest expansion relative to 
normal values correlated for age and sex. The individual must present with sacroiliitis 
with a grade of at least 2 bilaterally or a grade of 3 or 4 unilaterally. 
There now is a new classification criterion for AxSpA, which includes AS. 
Patients satisfy the criterion for AxSpA if they have active inflammation on magnetic 
resonance imaging (MRI), highly suggestive of sacroiliitis, or definite radiographic 
sacroiliitis according to the modified New York criteria. Furthermore, individuals must 
have one feature of AxSpA or HLA-B*27 positivity and two features of AxSpA. Our 
study focuses on AS patients rather than AxSpA, as those with AxSpA may have no 
radiographic changes. Thus, it would have been difficult to follow radiographic 
progression using radiographs. 
 
 
 
 
	   
Table	  2-­‐1:	  	  1984	  Modified	  New	  York	  Criteria	  for	  diagnosis	  of	  Ankylosing	  Spondylitis.	  Patients	  must	  have	  one	  clinical	  criteria	  and	  one	  radiological	  criteria	  for	  diagnosis	  	  
	  
Clinical	  Criteria	  –	  One	  of	  the	  following:	  
	  
▪ Low	  back	  pain	  ≥	  3	  months,	  improved	  by	  exercise	  and	  not	  relieved	  by	  rest	  	  
▪ Limitation	  of	  lumbar	  spine	  in	  sagittal	  and	  frontal	  planes	  (relative	  to	  normal	  values	  corrected	  for	  age	  and	  sex)	  	  
▪ Limitation	  of	  chest	  expansion	  (relative	  to	  normal	  values	  corrected	  for	  age	  and	  sex)	  	  
	  
Radiological	  Criteria	  –	  One	  of	  the	  following:	  
	  
▪ Bilateral	  grade	  2-­‐4	  sacroiliitis	  	  
▪ Unilateral	  3-­‐4	  sacroiliitis	  	  
Grading	  system	  for	  sacroillitis	  	  1.	  Grade	  0:	  normal	  2.	  Grade	  I:	  some	  blurring	  of	  the	  joint	  margins	  -­‐	  suspicious	  3.	  Grade	  II:	  minimal	  sclerosis	  with	  some	  erosion	  4.	  Grade	  III:	  definite	  sclerosis	  on	  both	  sides	  of	  joint	  or	  severe	  erosions	  with	  widening	  of	  joint	  space	  with	  or	  without	  ankylosis	  5.	  Grade	  IV:	  complete	  ankylosis	  	  	  
2.4 - Data Collection 
 
 
 
2.4.1 - Clinical Data 
 The	   clinical	   information	   used	   in	   this	   study	   was	   collected	   from	   the	   SPARCC	  database.	   The	   Spondylitis	   Consortium	   of	   Canada	   is	   a	   large	   national	   network	   that	  prospectively	   evaluates	   AS	   and	   PsA	   patients	  with	   a	   detailed,	   standardized	   protocol.	  
	   
The	   data	   is	   captured	   prospectively	   as	   patients	   are	   seen	   in	   this	   clinic	   every	   6	   to	   12	  months	  after	  entry	  to	  the	  clinic.	  Three	  major	  sites,	  Newfoundland,	  Ontario	  and	  Alberta	  account	  for	  over	  90%	  of	  the	  patients.	  This	  study	  used	  data	  that	  was	  collected	  from	  this	  consortium.	  As	  the	  events	  captured	  were	  already	  manifested	  from	  this	  consortium,	  it	  is	   felt	   that	   this	   is	   retrospective	   case	   only	   study,	   as	   all	   patients	   had	   ankylosing	  spondylitis.	   The	   case	   was	   then	   stratified	   based	   on	   presence	   or	   absence	   of	   extra-­‐articular	   features.	   Only	   patients	   of	   Northern	   European	   Ancestry	   were	   collected	   in	  these	   cohorts	   in	   an	   attempt	   to	   reduce	   population	   stratification	  with	   candidate	   gene	  studies.	   	   Since	   all	   patients	   were	   self-­‐reported	   to	   be	   Caucasians,	   ethnicity	   was	   not	  considered.	   The	   cohort	   consists	   of	   patients	  with	   AS	   referred	   to	   the	   clinic	   by	   family	  physicians	   and	   other	  medical	   specialists.	   All	   information	   is	   collected	   on	   a	   protocol,	  which	   includes	   clinical,	   laboratory	   and	   radiographic	   features	   updated	   on	   12-­‐month	  intervals.	  The	  radiologic	  assessments	  were	  performed	  at	  the	  University	  of	  Toronto	  on	  selected	  patients	   at	   2-­‐	   to	  3-­‐year	   intervals.	   There	  were	   two	   radiological	   assessments	  for	  a	   subset	  of	  our	  AS	  patients.	  The	   first	   radiological	   scoring	   that	  was	  available	  was	  referred	  to	  as	  mSASSS1.	  This	  score	  was	  used	  to	  assess	  disease	  severity.	   	  For	  patients	  that	   had	   a	   second	   mSASSS	   score	   available	   at	   a	   later	   point	   were	   referred	   to	   as	  mSASSS2.	   The	   mSASSS1	   and	   mSASSS2	   values	   were	   used	   to	   determine	   the	   rate	   of	  change	  of	  X-­‐ray	  progression.	  Only	  76	  patients	  have	  serial	  radiographs	  as	  collection	  of	  the	  X-­‐rays	  only	  began	  to	  answer	  a	  clinical	  question.	  After	  routine	  use	  of	  TNF	  inhibitors	  for	   the	   treatment	   of	   AS,	   a	   study	   of	   AS	   patients	   on	   biologics	   was	   compared	   to	   a	  historical	  control	  of	  about	  100	  patients	  demonstrated	  that	  these	  biologic	  agents	  may	  not	   be	   inhibiting	   the	   radiographic	   progression	   of	   this	   entity.	   In	   order	   to	   assess	   this	  
	   
question,	  an	  investigator	  from	  the	  SPARCC	  network	  started	  doing	  serial	  spinal	  X-­‐rays.	  This	  is	  not	  necessarily	  within	  the	  standard	  of	  care	  for	  most	  physicians.	  To	  the	  best	  of	  our	   knowledge	   the	   samples	  were	   consecutive	   samples	   that	   attend	   the	  U	   of	   T	   clinic,	  where	  the	  patients	  consented	  to	  repeat	  radiographs.	  It	  is	  from	  this	  cohort	  that	  the	  76	  patients	  were	  obtained.	  Patients	  were	  not	  selected	  for	  any	  specific	  trait,	  and	  also	  did	  not	   appear	   to	   have	   severe	   radiographic	   disease.	   This	   is	   because	   the	   median	  radiographic	   progression	   for	   this	   group	   is	   one	  mSASSS	   unit	   per	   year,	  which	   is	   very	  similar	  to	  what	  is	  reported	  in	  the	  literature.	  	  
With respect to the specific variables in our study, the patients completed 
questionnaires regarding their demographic information. Physicians collected histories at 
onset of AS and presence of any extra-articular manifestations, particularly IBD, 
psoriasis and uveitis at any point in their disease course. Comorbidities were recorded if 
individuals had a history of the disease, not if the disease was present at the time of 
examination. 
In all three AS cohorts, smoking history was collected by physicians and coded 
on the basis of whether the individual had ever smoked or never smoked. The occiput to 
wall measurement was collected for the Newfoundland and Toronto cohorts while the 
University of Alberta cohort collected occiput to wall and tragus to wall measurements. 
The occiput to wall value used in this report was collected upon the patient’s most recent 
visit with the physician. The total number of enthesitis was collected for the patients 
from all three cohorts. The enthesitis value collected at the individual’s first physician 
visit was used for this report. All information was previously recorded in the SPARCC 
database and was extracted for all locations commencing September 12, 2012. 
	   
2.4.2 - Genetic Data 
 
Part 1: 
2.4.2a	  -­‐	  CNV	  Information:	  UGT2B17	  Gene	  
 The	  initial	  detection	  of	  a	  significant	  association	  between	  UGT2B17	  in	  copy	  number	  2	  and	  AS	  was	  in	  a	  large	  multiplex	  family.	  In	  summary,	  a	  custom	  microarray	  was	  used	  to	   genotype	   CNVs.	   Validation	   of	   the	   CNV	   estimation	   of	   the	   UGT2B17	   gene	   was	  performed	   using	   the	   Taqman	   copy	   number	   assay	   Hs03185327_cn	   (Life	  Technologies)	  using	  the	  manufacturer’s	  recommended	  protocol.	  
The custom genome-wide microarray used to identify the UGT2B17 CNV in 
affected individuals has been previously described (Uddin et al., 2013; Uddin et al., 
2011). The microarray was covered with 2 X 1 million probes that were spaced with a 
mean of 280bp (Uddin et al., 2013). For this study, this unique assay was used to analyze 
CNV in 896 patient DNA samples. The samples were extracted from a comprehensive 
biobank located in the Health Sciences Center at Memorial University. The bank 
contains the genetic information of the SpA patients belonging to the cohorts from 
Newfoundland, Toronto and Alberta. DNA samples were pipetted into 96 well trays at 
10 ng/µg and analyzed for CNV count at The Center for Applied Genomics (TCAG) in 
Toronto using the Taqman copy number assay Hs03185327_cn (Life Technologies). 
Part 2: 
2.4.2b - Selection of Related Smoking SNPs 
 
The genetic information from the biobank was used to analyze related smoking 
SNPs. In total, 36 SNPs were selected. The DNA of individuals with available smoking 
history information was pipetted into 96 well trays at 10 ng/µg. The smoking SNPs were 
	   
then genotyped using the Sequenom MassARRAY system (iPLEX GOLD). Smoking 
SNPs were chosen from five genes that have been known to be associated with either AS 
or the nicotine metabolism pathway (Table 2-2). 
 
 
Table	  2-­‐2:	  SNP	  IDs	  with	  associated	  genes	  
 
SNP ID Gene 
 
rs62003625 CHRNA7 
rs4779565 CHRNA7 
rs28531779 CHRNA7 
rs261160 CHRNA7 
rs6494223 CHRNA7 
rs76336281 CHRNA7 
rs12916879 CHRNA7 
rs6494216 CHRNA7 
rs12908877 CHRNA7 
rs78383742 CHRNA7 
rs75599783 CHRNA7 
rs79184402 CHRNA7 
rs885071 CHRNA7 
rs13329490 CHRNA7 
rs11636680 CHRNA7 
rs11636680 CHRNA7 
rs113629315 CHRNA7 
rs1355920 CHRNA7 
rs4779978 CHRNA7 
rs10438340 CHRNA7 
rs10438341 CHRNA7 
rs2133965 CHRNA7 
rs11852727 CHRNA7 
rs7167551 CHRNA7 
rs141124772 CHRNA7 
rs7178176 CHRNA7 
rs60109258 CHRNA7 
rs202192566 CHRNA7 
rs374853 CHRNA7 
rs60056915 CHRNA7 
rs115291806 CHRNA7 
rs2337503 CHRNA7 
rs111910242 CHRNA7 
rs2337506 CHRNA7 
	   
rs115112505 CHRNA7 
rs11071593 CHRNA7 
rs188889623 CHRNA7 
rs7172276 CHRNA7 
rs12910885 CHRNA7 
rs4349859 HLA-B*27 
rs1800925 IL-13 
rs61750900 UGT2B10 
rs72551387 UGT2B17 
 
 
 
 
First, in HLA-B*27, the gene most strongly associated with AS heritability, a 
single tag-SNP (rs4349859) was located and genotyped. We next identified a single tag- 
SNP (rs1800925) within the IL-13 gene to investigate whether the same protective effect 
of IL-13 polymorphisms in psoriasis progression is present in AS patients (Duffin et al., 
2009; Eder, et al., 2010). For the purpose of this study, 36 SNPs located within the 
cholinergic receptor, nicotinic, alpha 7 (CHRNA7) gene, which is involved in receptor 
presentation in the nicotine pathway, were genotyped. A single tag-SNP located in every 
LD block within the CHRNA7 gene was selected for genotyping (Rothem et al., 2009). 
Additionally, the SNP (rs61750900) in the Asp67Tyr allele located in the UGT2B10 
gene and the SNP (rs72551387) in the Asp85Tyr allele located in the UGT2B17 gene 
were genotyped (Berg et al., 2010; Chen  et  al.,  2010).  Given their roles in the   
nicotine pathway, it is appropriate to investigate these genes for the effects of smoking 
on AS susceptibility and pathogenesis. 
 
2.4.2c	  -­‐	  Genotyping	  of	  Related	  Smoking	  SNPs	  
 
Genotyping of the relevant SNPs was done using the Sequenom MassARRAY 
system (Danoy et al., 2010). The system was operated as per the protocol stated by the 
manufacturer, Agena. The polymerase chain reaction (PCR) amplification used a unique 
	   
primer constructed by the MassARRAY custom design software. Two multiplex assays 
were designed for each AS sample. Originally, 43 SNPs were submitted for design, 
however only 36 SNPS had data relevant to the analysis. Each custom assay consisted of 
36 SNPs and was constructed using Sequenom’s Assay Design Suite 1.0. The products 
of the Sequenom reactions were dispensed onto a 96 element Spectrochip bioarray using 
the MassARRAY nanodispenser. The SNPs were assayed on the OpenARRAY 
genotyping platform. The products were detected and genotyped using iPLEX chemistry 
on a matrix assisted laser desorption/ionization time-of-flight (MALDI_TOF) mass 
spectrometer. MassARRAY typer software was then used to identify the genotypes 
present in the assays. 
 
2.5 - Sample Size 
 
The minimum sample size calculation for part 1 of the objectives was based upon 
previous research of the UGT2B17 copy number in AS patients by Uddin et al. (2013) 
found in the Newfoundland and Alberta populations. Considering that the primary 
outcome of interest for this study is dichotomous and that the results are being assessed 
in a one-sided testing fashion, the results of the previous paper were used to estimate a 
larger sample size. 
Based on the known frequency of the CNV from previous studies, a frequency of 
40% was used for two or more copies of UGT2B17. With the assumption of a 10% 
difference in the allele frequency, a total of 200 patients were needed for an 80% power 
(i.e. β = 0.20; α = 0.05). A breakdown of additional sample sizes is also presented (Table 
2-3). 
 
	   
Table 2-3: Sample size calculations based on varying power indexes for Part 1 
 
 	   N 	  
Index Total Power 
1 100 0.535 
2 200 0.839 
3 300 0.954 
4 400 0.988 
5 500 0.997 
6 600 >0.999 
7 700 >0.999 
8 800 >0.999 
 
 
 
Power for the regression analysis performed to evaluate Part 2 of the objectives was calculated 
based on a 50% change of the mean value for either severity or progression. The calculation 
was completed assuming 38 patients per group. These assumptions considered will give 29.8% 
power to detect a difference of 4.35 in mSASSS1, which is 50% of the mean, and 20.6% 
power to detect a difference of 0.525 in progression, which is 50% of the mean. 
2.6 - Statistical Analysis 
 
SPSS Statistics v20 was used for data analysis. 
 
2.6.1 - Data Organization and Coding 
 
 
 
2.6.1a	  -­‐	  Variables:	  Extra-­‐Articular	  Features,	  HLA-­‐B*27	  and	  UGT2B17	  
 
The data from the three sites was initially entered and organized into a Microsoft 
	   
Excel spreadsheet after being extracted from the SPARCC database. The dichotomous 
and categorical variables were entered with a numerical code. 	  	  	  	  	  Dichotomous	   data	  were	   available	   for	   the	   following	   clinical	   variables:	   gender,	  
UGT2B17	  CNV,	   IBD	   history,	   psoriasis	   history,	   uveitis	   history,	  HLA-­‐B*27	   status	   and	  smoking	   history.	   Gender	   was	   coded	   as	   “1”	   being	   female	   and	   “2”	   being	   male.	   IBD,	  psoriasis	  and	  uveitis	  were	  analyzed	  as	  dichotomous	  variables	  by	  coding	  “0”	  as	  “no,	  never	  presented	  with	  the	  feature,”	  and	  “1”	  as	  “yes,	  presently	  has	  the	  feature	  or	  once	  had	   the	   feature.”	  For	  HLA-­‐B*27	  status,	  positive	  was	   coded	  as	   “1”	   and	  negative	  was	  coded	  as	   “0.”	  Smoking	  history	  was	  coded	  as	   “0”	   for	   “no,	  never	  smoked,”	  and	  “1”	  as	  “yes,	   currently	   smoking	   or	   was	   a	   past	   smoker.”	   For	   the	   primary	   analysis,	   AS	  individuals	  were	  divided	  into	  two	  groups	  based	  upon	  UGT2B17	  CNV.	  One	  group	  was	  “CNV	  2”	  consisting	  of	  individuals	  with	  2	  or	  more	  copies	  of	  the	  UGT2B17	  gene	  while	  the	  second	  group	  was	  “CNV	  ≤	  1”	  consisting	  of	  individuals	  with	  CNV	  0	  or	  1.	  CNV	  was	  coded	  as	  CNV	  0	  or	  1	  and	  CNV	  2	  because	  a	  previous	  study	  by	  Uddin	  et	  al	  2013	  found	  that	   CNV	   2	   was	   significantly	   associated	   with	   AS	   in	   a	   multiplex	   family.	   CNV	   2	  represents	   the	   wildtype	   gene	   and	   CNV	   0	   and	   1	   represent	   polymorphisms.	   Our	  analysis	   aims	   to	   determine	   whether	   the	   wildtype	   allele,	   that	   was	   significantly	  associated	  with	  AS	   in	  a	  multiplex	   family,	   is	  also	  associated	  with	   the	  extra-­‐articular	  features	  of	  AS.	  	  We	  group	  CNVs	  in	  this	  way	  because	  we	  are	  using	  previous	  significant	  findings	   and	   expanding	   on	   them	   in	   a	   larger	   cohort	   to	   determine	   whether	   disease	  expression	  can	  be	  explained	  by	  the	  same	  allele	  frequency.	  	  
Physician Global Health Rating, written as DRGLOBAL, is an ordinal variable 
and was coded as “1” for “very good,” “2” for “good,” “3” for “fair,” “4” for “poor” and 
	   
“5” for “very poor.” Occiput to wall and age of onset of AS were measured on a 
continuous scale. The organized and coded data was then moved into SPSS Statistics v20 
for analysis. 	  
2.6.1b	  -­‐	  Variables:	  Smoking	  SNPs	  and	  Attached	  Clinical	  Information	  
 
The results from the Sequenom MassARRAY system were organized into 
Microsoft Excel 2010 by SNP rs numbers. Genotype call information was divided into 
36 SNP rs numbers. Each patient was matched to his or her corresponding genotype call 
and clinical information by SNP rs numbers. The organized and coded data was then 
moved into SPSS Statistics v20 for analysis. 
 
 
2.6.2 - Variables: Data Filtering 
 	  	  	  	  	  Any	   AS	   patients	   with	   missing	   phenotype	   information	   for	   the	   variable	   under	  examination	  was	   removed	   from	   the	   analysis	   using	   a	   specially	   designed	   algorithm.	  Any	  smoking	  SNP	  with	  a	  single	  genotype	  call	  was	  removed	  from	  the	  analysis	  using	  the	   same	   algorithm.	   Also,	   any	   SNP	   failing	   the	  Hardy	  Weinberg	   equilibrium	   (HWE)	  was	   excluded	   from	   the	   analysis.	   Originally	   43	   SNPs	   were	   submitted	   for	   design;	  however,	  7	  SNPs	  produced	  no	  genotype	  calls	  due	  to	  poor	  multiplex	  design.	  This	  left	  36	   SNP's	   for	   analysis.	   	   In	   Sept.	   2015,	   the	   rs	   188889623	   SNP	   was	   excluded	   from	  analysis	   due	   to	  poor	  performance	   (i.e.,	   high	  UEP,	   low	  peaks).	   This	   brought	   the	   list	  down	  to	  35	  SNPs.	  From	  this	  list	  of	  35,	  11	  SNPs	  failed	  to	  produce	  a	  genotype	  call	  for	  at	  least	  1	  sample,	  leaving	  24	  SNPs	  for	  subsequent	  analysis.	  From	  this	  list	  of	  24	  SNPs,	  7	  
	   
SNPs	   were	   uninformative	   meaning	   that	   all	   samples	   produced	   the	   same	   genotype.	  Therefore,	  17	  SNPs	  were	  included	  in	  the	  final	  analysis.	  
 
2.6.3 - Data Analysis 
 Comparisons	  involving	  the	  two	  UGT2B17	  CNV	  groups	  with	  another	  dichotomous	  variables	   were	   done	   using	   Chi-­‐	   square	   analysis.	   A	   Chi-­‐squared	   test	   is	   a	   statistical	  analysis	  that	  is	  used	  to	  evaluate	  the	  likelihood	  that	  an	  observed	  difference	  between	  two	   sets	   of	   categorical	   data	   occurred	   by	   chance.	   It	   tests	   a	   null	   hypothesis	   that	   no	  difference	   is	   observed	   between	   outcomes	   and	   each	   outcome	   is	   equally	   likely	   to	  occur.	  When	  the	  null	  hypothesis	  is	  true,	  the	  data	  follows	  a	  chi-­‐	  squared	  distribution.	  Rejection	  of	   the	  null	  hypothesis	   indicates	   that	   the	  data	  sets	  are	  not	   independent.	  A	  Fisher’s	  exact	  test	  is	  another	  statistical	  analysis	  that	  it	  used	  to	  evaluate	  contingency	  tables	  of	  categorical	  data.	  It	  also	  tests	  a	  null	  hypothesis	  that	  each	  outcome	  is	  equally	  likely	  to	  occur;	  however,	  a	  Fisher’s	  exact	  test	  is	  used	  for	  data	  with	  small	  sample	  size	  and	  is	  only	  applicable	  to	  data	  when	  at	  least	  one	  cell	  of	  the	  contingency	  table	  is	   less	  than	  or	  equal	  to	  5.	  For	  this	  reason	  we	  use	  the	  Chi-­‐squared	  test	  in	  our	  analysis	  as	  all	  cells	  observed	  in	  our	  contingency	  tables	  are	  greater	  than	  5.	  Two-­‐tailed	   tests	   were	   used	   instead	   of	   one-­‐tailed	   tests	   in	   the	   assessment	   of	  whether	   CNV	   2	   was	   found	   to	   be	   more	   often	   associated	   with	   the	   extra-­‐articular	  features	  of	  AS	  and	  HLA-­‐	  B*27.	  It	  is	  possible	  that	  two	  copies	  of	  the	  UGT2B17	  gene	  may	  be	   more	   or	   less	   frequent	   in	   a	   subset	   of	   AS	   patients	   with	   extra-­‐articular	  manifestations	  when	  compared	  to	  AS	  patients	  exhibiting	  no	  extra-­‐articular	  features.	  Our	  null	  hypothesis	  states	  that	  the	  number	  of	  individuals	  with	  CNV	  of	  2	  is	  the	  same	  in	  both	  the	  patient	  group	  with	  extra-­‐articular	  features	  or	  HLA-­‐B*27	  positivity	  and	  the	  
	   
group	   without	   extra-­‐articular	   features	   or	   HLA-­‐B*27	   positivity.	   Our	   alternative	  hypothesis	  is	  that	  the	  CNV	  groups	  are	  different	  between	  the	  two	  patient	  groups.	  	  
Associations between known smoking SNPs and disease severity and progression 
were evaluated using a multiple linear regression. The linear regression was controlled 
for  age, gender and smoking habit. 
 
2.6.3a	  -­‐Part	  1:	  	  UGT2B17	  CNV	  and	  Extra-­‐Articular	  Features	  
 
The associations of UGT2B17 CNV with the extra-articular features of AS, IBD, 
psoriasis and uveitis were compared using the Chi-squared test. The comparison was 
done at a level of significance of p ≤ 0.05. 
 
 
2.6.3b	  –	  Part	  1:	  UGT2B17	  CNV	  and	  HLA-­‐B*27	  
 
The gene-gene interaction of UGT2B27 with HLA-B*27 was tested using the 
Chi-squared test for association. This comparison was done at a level of significance of p 
≤ 0.05. 
2.6.3c	  –	  Part	  2:	  Disease	  Severity	  and	  Genotypes	  
 
A multiple linear regression was used to determine the association between each SNP 
and the mean values of mSASSS1. For the purposes of the analyses in the study, 
univariate analysis with each SNP was not performed. Instead, to evaluate the mSASSS 
data there were four variables and one interaction term in the regression models. The 
multiple linear regressions were controlled for age, gender and smoking habit. In this 
analysis three inheritance models were examined: additive, dominant and recessive. For 
each genotype, the HWE was tested, and only those SNPs which follow the HWE were 
included. An interaction term between smoking habit (“yes” versus “no”) and each SNP 
	   
was introduced into the multiple linear regression models to examine the association 
among smokers and non-smokers, respectively. Dependent variables used in the 
multivariate regression analysis were both mSASSS1 and progression.  
 
2.6.3d	  –	  Part	  2:	  Disease	  Progression	  and	  Genotypes	  
 
A multiple linear regression was used to determine the association between each 
SNP and the mean values of disease progression. The multiple linear regressions were 
controlled for age, gender and smoking habit. In this analysis the same three inheritance 
models were examined. For each genotype, the HWE was tested, and only those SNPs 
which follow the HWE were included. An interaction term between smoking habit (“yes” 
versus “no”) and each SNP was introduced into the multiple linear regression models to 
examine the association among smokers and non-smokers, respectively. A common 
element of genetic studies is to assess multiple genetic variants with a very small sample 
set. Multiple testing must be taken into account when performing candidate genetic 
testing. As long as the SNPs are not in linkage disequilibrium, the most straightforward 
way to account for multiple testing is the use the Bonferroni’s correction. For larger 
sample sets such as a genome wide association study, the calculation of a false discovery 
rate can be used, as many SNPs are in linkage disequilibrium. Thus Bonferroni’s 
correction is too conservative in this case.  For each given SNP, they were assessed using 
additive and multiplicative models. Genetic interactions are often difficult to measure and 
interpret, as statistical interactions do not necessarily lead to biological interactions. 
Gene-gene interaction was assessed for HLA-B*27 and UGBT17, as stated in the above 
section. 
	   
 
 
 
 
 
 
3	  
 
Results	  
	   
 
3.1 -Part 1:  UGT2B17 Copy Number Variants and Extra-articular features in SpA 
 
 
 
3.1.1 - Demographics 
 
Of the 896 AS patients from Newfoundland, Toronto and Alberta, 555 (61.9%) 
were male while 341 (38.1%) of the patients were female. The patients were all analyzed 
for CNV of the UGT2B17 gene. Of the 896 patients, 625 (69.8%) had available family 
history information. Of these, 448 (78.1%) did not have a family history of AS and 137 
(21.9%) individuals had an affected family member. Of the 896 patients, 587 (65.5%) 
individuals had available smoking history information. Of these cases, 312 (52.3%) 
individuals had never smoked and 275 (46.8%) individuals had smoked, past or present 
(Table 3-1). 
Additional frequency analysis was completed for UGT2B17 alleles in each of the 
three populations analyzed. Of the 166 patients in the Newfoundland population 71 
(43%) patients had CNV 2 and 95 (57%) had CNV 0 or 1. Of the 503 patients in the 
Toronto population, 183 (36%) had CNV 2 while 320 (64%) had CNV 0 or 1. Of the 227 
patients in the Alberta population, 92 (41%) had CNV 2 and 135 (59%) had CNV 0 or 1 
(Table 3-2) 
 
 
 
 
 
 
 
 
 
 
 
 
	   
Table 3-1: Demographic information for AS patients in a cohort of 896 patients 
 
Clinical Information Values 
Male 61.9% 
Family History of AS 21.9% 
Smoking 46.8% 
 
 
 
Table 3-2: CNV Frequency in the three populations analyzed 
 
Population	  
	  
CNV	  2	  Frequency	   CNV	  ≤	  1	  Frequency	  Newfoundland	  	   71	  (43%)	   95	  (57%)	  Toronto	  	   183	  (36%)	   320	  (64%)	  Alberta	  	   92	  (41%)	   135	  (59%)	  	  
 
 
3.1.2 -UGT2B17 CNV and AS Extra-Articular Features 
 
Of the 896 patients identified by the UGT2B17 CNV, 548 (61.2%) individuals expressed 
0 or 1 copy of the gene and 348 (38.8%) individuals expressed 2 or more copies of the 
gene. The two CNV groups were then compared for frequencies of IBD, psoriasis and 
uveitis. Of the 896 patients identified by the UGT2B17 CNV, 602 had available IBD 
history information. Of these patients, 486 individuals (80.7%) self- reported having 
never had symptoms of IBD and 116 patients (19.3%) reported a history of IBD 
symptoms. Between IBD and UGT2B17 CNV, 308 patients had CNV 0 or 1 and never 
had IBD; 67 patients had CNV 0 or 1 and an IBD history; 178 patients had CNV 2 and 
never had IBD; and 49 patients had CNV 2 and an IBD history (Table 3-3; Figure 3- 1). 
Using the two-sided Chi-Squared test, no association was found between having 
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UGT2B17 CNV 2 and ever having IBD (p-value = 0.262).  
 
 
Table 3-3: Contingency table of CNV categories and history of IBD used in the Chi- 
square test analysis 
CNV CALLS IBD NO IBD 
≤1 67 (0.58) 308 (0.63) 
2 49 (0.42) 178 (0.37) 	  	  
	  	  	  
Fig	  3-­‐1:	  Proportions	  of	  individuals	  with	  2	  copies	  of	  the	  UGT2B17	  gene	  having	  self-­‐	  
 
reported IBD and never having self-reported IBD 
 
 
 
Psoriasis history information was available for only 385 of the patients with CNV 
information. Of the total patients with psoriasis, 325 individuals (84.4%) reported never 
experiencing symptoms of psoriasis while 60 patients (15.6%) reported a history of 
psoriasis. Between psoriasis and UGT2B17 CNV: 196 patients had CNV 0 or 1 and never 
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had psoriasis; 37 patients had CNV 0 or 1 and a psoriasis history; 129 patients had CNV 2 
and never had psoriasis; and 23 patients had CNV 2 and a psoriasis history. Using the two-
sided Chi-Squared test, no association was found between having UGT2B17 CNV 2 and 
ever having psoriasis (p-value = 0.843; Table 3-4; Figure 3-2). 
Table 3-4: Contingency table of CNV categories and history of psoriasis used in the Chi- 
square test analysis 
CNV CALLS PSORIASIS NO PSORIASIS 
≤1 37 (0.62) 196 (0.60) 
2 23 (0.38) 129 (0.40) 
 
 
 
Fig	  3-­‐2:	  Proportions	  of	  individuals	  with	  2	  copies	  of	  the	  UGT2B17	  gene	  having	  self-­‐	  
 
reported psoriasis and never having self-reported psoriasis 
 
 
 
Of the total patient group, 771 individuals had available uveitis information. Of 
these, 522 patients (67.7%) reported never having uveitis and 249 patients (32.3%) 
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reported a history of uveitis. Chi- squared test for association was preformed between 
CNV groups and each extra-articular feature separately. Between uveitis and UGT2B17 
CNV: 326 patients had CNV 0 or 1 and never had uveitis; 154 patients had CNV 0 or 1 
and a uveitis history; 196 patients had CNV 2 and never had uveitis; and 95 patients had 
CNV 2 and a uveitis history. Using a two-sided Chi-squared test, no association was 
found between having UGT2B17 CNV 2 and ever having uveitis (p-value = 0.871; Table 
3-5; Figure 3-3). 
 
Table 3-5: Contingency table of CNV categories and history of uveitis used in the Chi- 
square test analysis 
CNV CALLS UVEITIS NO UVEITIS 
≤1 154 (0.62) 326 (0.62) 
2 95 (0.38) 196 (0.38) 
 
 
 
Fig	  3-­‐3:	  Proportions	  of	  individuals	  with	  2	  copies	  of	  the	  UGT2B17	  gene	  having	  self-­‐	  
 
reported uveitis and never having self-reported uveitis
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3.1.3 - Gene-Gene Interaction: UGT2B17 CNV and HLA-B*27 Status 
 
Of the 896 patients identified with the UGT2B17 CNV, 754 of the patients had 
been tested for HLA-B*27 positivity. Of these 754 patients, 601 patients (79.7%) tested 
positive for the HLA-B*27 gene and 153 (20.3%) patients tested negative for the HLA- 
B*27 gene. Between UGT2B17 CNV status and HLA-B*27 status: 102 individuals had 
CNV 0 or 1 and tested negative for HLA-B*27; 367 had CNV 0 or 1 and tested positive 
for HLA-B*27; 51 patients had CNV 2 and tested negative for HLA-B*27; and 234 
patients had CNV 2 and tested positive for HLA-B*27. Using a two-sided Chi-squared 
test, no association was found between UGT2B17 CNV 2 and HLA-B*27 positivity (p- 
value = 0.202; Table 3-7; Figure 3-4). 
Table 3-7 summarizes CNV frequencies in the four extra-articular feature groups. 
 
 
 
Table 3-6: Contingency table of CNV categories and HLA-B*27 status used in the Chi- 
square Fisher’s exact test analysis 
CNV CALLS HLA-B*27 NO HLA-B*27 
≤1 367 (0.61) 102 (0.67) 
2 234 (0.39) 51 (0.33) 	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Fig 3-4: Proportions of individuals with 2 copies of the UGT2B17 gene with a positive 
 
HLA-­‐B*27	  status	  and	  a	  negative	  HLA-­‐B*27	  status	  
 
 
 
Table 3-7: Frequency of individuals having ever presented with each extra-articular 
feature and HLA-B*27 in each CNV category with associated p-values from statistical 
analysis using the Chi-squared test 
Clinical Features UGT2B17 CNV 0 
or 1 
UGT2B17 CNV 
2 
p-value 
History of IBD (n = 602) 67 (17.9%) 49 (21.6%) 0.262 
History of Uveitis (n = 771) 154 (32.1) 95 (32.6) 0.843 
History of Psoriasis (n = 
385) 
37 (15.9%) 23 (15.1%) 0.871 
HLA-B*27 Positivity 367 (78.2%) 234 (82.1%) 0.202 
0	  0.05	  
0.1	  0.15	  
0.2	  0.25	  
0.3	  0.35	  
0.4	  0.45	  
2	  copies	  of	  UGT2B17	  
HLA-­‐B*27	  	  No	  HLA-­‐B*27	  0.39	   0.33	  
	   
 
3.2 -Part 2:  Genetics of Radiographic Severity and Progression 
 
 
3.2.1 - Demographics 
 
Of the 75 patients used in the multiple linear regression analysis, 78% were male, 
40% had a smoking history and 76% were HLA-B*27 positive. The average onset of 
disease presentation in the 75 patients was 24.8 years; however, on average, the disease 
was not formally diagnosed until 31.2 years. An analysis was preformed to find an 
association with disease severity and disease progression with smoking SNPs. The 
radiographs used in the analysis were taken at an average of 3 years apart. Of the 75 
patients, 35 patients demonstrated a change in serial radiograph values above 0 (i.e. 
radiographic progression). The mean disease severity (i.e. mSASSS1) for the entire 75 
patients was 8.65, with a standard deviation of 13.22, and the mean mSASSS1 for the 35 
patients with radiographic progression was 14.65, with a standard deviation of 15.28. The 
mean disease progression value for the entire 75 patient cohort was 0.51, with a standard 
deviation of 0.9, and the mean disease progression value for the 35 patients demonstrating 
disease progression was 1.09, with a standard deviation of 1.14 (Table 3-8). 
 
Table 3-8: Demographics of AS patients in a cohort of 75 individuals with serial mSASS 
scores 
 
Clinical Information Values 
 
Male 78% 
Smoking 40% 
HLA-­‐B*27	  positive	  status	   76%	  
Average age of disease onset 24.8 years 
 
	   
 
 
Average age of diagnosis 31.2 years 
Average timeframe between serial radiographs 3 years 
Number of patients with radiographic progression 35 
(change in mSASSS score > 0) 
Mean disease severity (mSASSS1) for 75 patients 8.65 ± 13.22 
Mean disease severity (mSASSS1) for 35 patients 
with progression 
Mean disease progression per year for entire 75 
patients 
14.65 ± 15.28 
0.51 ± 0.9 
Mean disease progression per year for 35 patients with 
progression 
1.09 ± 1.14 
3.2.2 - Disease Severity and Smoking SNPs 
Analysis of the interaction between selected genetic variants, radiographic  
severity and both smoking status and sex was performed. Three inheritance models are 
described as dominant (CC or CT), recessive (TT), and additive (Appendix 2). Additive 
represents an allele dose effect by comparing 2 C alleles (CC), 1 C allele (CT) and 0 C 
alleles (TT). Four tables (Table 3-9, Table 3-10, Table 3-11 and Table 3-12) display the 
results of the analyses. Two SNPs were found to be significantly associated with disease 
severity, rs7178176 and rs11071593, both with a significant of p = 0.0005 for the 
dominant model and p = 0.001 for the genotype. Table 3-12 displays only SNPs with 
statistical significance. Both of these SNPs are located in the deep intronic region of 
CHRNA7 and play a role in the smoking and nicotine dependence pathway. 
	   
Table 3-9: Disease severity p-values in association with SNPs for genotypes 
 
SNPs for Genotype Disease Severity (mSASSS1) 
rs885071 0.6801 
rs1800925 0.2936 
rs2337506 0.2068 
rs4779565 0.8455 
rs4779978 0.441 
rs6494223 0.5751 
rs7167551 0.8284 
rs7178176 0.001 
rs11071593 0.0087 
rs11636680 0.8427 
rs12910885 0.2068 
rs12916879 0.8982 
rs13329490 0.8343 
rs60109258 0.4716 
rs61750900 0.2351 
rs62003625 0.4859 
rs113629315 0.2834 
 
 
 
 
Table 3-10: Disease severity and interaction with smoking p- values in association with 
SNPs for genotype 
 
 	  	   SNPs for Genotype Disease Severity (mSASSS1) and 
Interaction with Smoking 	   rs885071*smoking 0.7068 	   rs1800925*smoking 0.7014 	   rs2337506*smoking 0.686 	   rs4779565*smoking 0.6555 	   rs4779978*smoking 0.0127 	   rs6494223*smoking 0.7401 	   rs7167551*smoking 0.9237 	   rs7178176*smoking 0.5443 	   rs11071593*smoking 0.8752 	   rs11636680*smoking 0.592 	   rs12910885*smoking 0.686 	   rs12916879*smoking 0.2175 	   rs13329490*smoking 0.2391 
	   
 
rs60109258*smoking 0.3761 
rs61750900*smoking 0.0435 
rs62003625*smoking 0.5468 
rs113629315*smoking 0.6482 
* Indicates a variable interaction term 
 
 
 
Table 3-11: Disease severity and interaction with gender  p-values in association with 
SNPs for genotype 
 	   SNPs for Genotype Disease Severity (mSASSS1) and 	   	   Interaction with Gender 	   rs885071*gender 0.893 	   rs1800925*gender 0.2991 	   rs2337506*gender 0.8864 	   rs4779565*gender 0.9838 	   rs4779978*gender 0.5371 	   rs6494223*gender 
rs7167551*gender 
0.7823 
NA 	   rs7178176*gender 0.4092 	   rs11071593*gender 0.9793 	   rs11636680*gender 0.9437 	   rs12910885*gender 0.8864 	   rs12916879*gender 0.2319 	   rs13329490*gender 0.4007 	   rs60109258*gender 0.7092 	   rs61750900*gender 0.6313 	   rs62003625*gender 0.9363 	   rs113629315*gender 0.6234 
*Indicates a variable interaction term 
	   
 
Table	  3-­‐12:	  SNPs	  from	  the	  CHRNA7	  gene	  having	  significant	  association	  with	  disease	  severity	  
 
SNPs located in CHRNA7 Disease Severity (mSASSS1) 
 
rs7178176 Dominant model p = 0.0005 
 
Genotype p = 0.001 
 
rs11071593 Dominant model p = 0.0005 
Genotype p = 0.001 
 
 
 
3.2.3 - Disease Progression and Smoking SNPs 
 An	   analysis	   of	   the	   interaction	   between	   selected	   genetic	   variants,	   radiographic	  progression	  (change	  in	  mSASSS	  >	  0)	  and	  both	  smoking	  status	  and	  sex	  was	  performed.	  Three	   inheritance	  models	  are	  described	  as	  dominant	   (CC	  or	  CT),	   recessive	   (TT),	   and	  additive	   (Appendix	   2).	   Additive	   represents	   an	   allele	   dose	   effect	   by	   comparing	   2	   C	  alleles	   (CC),	   1	   C	   allele	   (CT)	   and	  0	   C	   allele	   (TT).	   Four	   tables	   (Table	   3-­‐13,	   Table	   3-­‐14,	  Table	  3-­‐	  15	  and	  Table	  3-­‐16)	  display	  the	  results	  of	  the	  analysis.	  Two	  SNPs	  were	  found	  to	  be	  significantly	  associated	  with	  disease	  progression,	  rs2337506	  and	  rs12910885.	  The	  SNP	   rs2337506	   was	   associated	   with	   disease	   progression	   with	   a	   significance	   of	   p	   <	  0.001	   for	   the	   recessive	  model	   and	  p	  =	  0.003	   for	   the	   genotype.	  The	   SNP	   rs12910885	  was	   associated	   with	   disease	   progression	   with	   a	   significance	   of	   p	   <	   0.0001	   for	   the	  recessive	  model	  and	  p	  =	  0.0001	  for	  the	  genotype.	  Table	  3-­‐16	  displays	  only	  SNPs	  with	  statistical	   significance.	  All	   SNPs	  were	   run	   in	  a	   likelihood	   ratio	   test	  with	   radiographic	  progression.	   Each	   SNPs	   was	   run	   separately	   in	   its	   own	   model	   with	   radiographic	  progression.	  The	   two	  SNPs	   listed	   in	  Table	  3-­‐16	  were	   the	   SNPs	   that	  were	   significant.	  
	   
Both	  of	  these	  SNPs	  are	  located	  in	  the	  deep	  intronic	  region	  of	  CHRNA7	  and	  play	  a	  role	  in	  the	   smoking	   and	   nicotine	   dependence	   pathway.	   The	   final	   analysis	   evaluates	   the	  genetics	   of	   radiographic	   progression	   in	   AS	   using	   selected	   smoking	   related	   genetic	  variants.	  
Table 3-13: Disease progression p-values in association with SNPs for genotypes 
 
SNPs for Genotype Disease Progression 
rs885071 0.071 
rs1800925 0.1384 
rs2337506 0.0003 
rs4779565 0.7416 
rs4779978 0.1038 
rs6494223 0.2132 
rs7167551 0.3206 
rs7178176 0.1913 
rs11071593 0.1155 
rs11636680 0.0771 
rs12910885 0.0003 
rs12916879 0.0648 
rs13329490 0.6645 
rs60109258 0.2028 
rs61750900 0.5182 
rs62003625 0.6831 
rs113629315 0.7398 
 
 
Table 3-14: Disease progression and interaction with smoking p-values in association 
with SNPs for genotype 
SNPs for Genotype Disease Progression and Interaction 
with Smoking 
rs885071*smoking 0.5936 
rs1800925*smoking 0.1493 
rs2337506*smoking 0.5652 
rs4779565*smoking 0.9462 
rs4779978*smoking 0.3521 
rs6494223*smoking 0.8224 
rs7167551*smoking 0.4022 
rs7178176*smoking 0.3499 
rs11071593*smoking 0.1144 
	   
 
rs11636680*smoking 0.184 
rs12910885*smoking 0.5652 
rs12916879*smoking 0.2824 
rs13329490*smoking 0.5582 
rs60109258*smoking 0.6555 
rs61750900*smoking 0.662 
rs62003625*smoking 0.7252 
rs113629315*smoking 0.1655 
*Indicates a variable interaction term 
 
 
 
Table 3-15: Disease progression and interaction with gender p-values in association with 
SNPs for genotype 
SNPs for Genotype Disease Progression and Interaction 
with gender 
rs885071*gender 0.3719 
rs1800925*gender 0.9572 
rs2337506*gender 0.2218 
rs4779565*gender 0.9991 
rs4779978*gender 0.7992 
rs6494223*gender 0.9382 
rs7167551*gender NA 
rs7178176*gender 0.33 
rs11071593*gender 0.8648 
rs11636680*gender 0.5848 
rs12910885*gender 0.2218 
rs12916879*gender 0.8 
rs13329490*gender 0.9888 
rs60109258*gender 0.9042 
rs61750900*gender 0.7772 
rs62003625*gender 0.7536 
rs113629315*gender 0.8443 
*Indicates a variable interaction term 
	   
 
Table	  3-­‐16:	  SNPs	  from	  the	  CHRNA7	  gene	  having	  significant	  association	  with	  disease	  progression	  
 
SNPs located in CHRNA7 Disease Progression 
 
rs2337506 Recessive model p < 0.001 
 
Genotype p = 0.0003 
 
rs12910885 Recessive model p < 0.0001 
Genotype p = 0.0001 
 
 
 
Table 3-17 displays the significant results of comparing progression values 
between non- smokers and smokers with the addition of C allele in the genotype for the 
rs1800925 SNP. The addition of a C allele in the genotype was not associated with 
progression in non-smokers. The addition of a C allele in the genotype was significantly 
associated with progression in smoking patients. The R squared value in this multivariate 
regression analysis of progression with rs1800925 was 0.22.  
 
Table 3-17: Comparison of progression values between non-smokers and smokers with 
the addition of C allele in the genotype for the rs1800925 SNP 
Smoking Status Β-value of progression P-value 
Non-Smoker 0.64 0.2348 
Smoker -1.34 0.0497 
 
 
Table 3-18 shows significant comparisons of mSASSS1 values between non- 
smokers and smokers with GG, GT, and TT genotypes for the rs61750900 SNP. There 
was no significant association between the SNP rs61750900 and mSASSS1 in non- 
	   
 
smokers. Smokers with GT genotype had significantly lower mSASSS1 than those with 
GG.  The R squared value in this multivariate regression analysis of mSASSS1 with 
rs61750900 was 0.28. 
The SNP rs61750900 is a regulatory region variant found in the UGT2B10 gene, 
which produces one of three enzymes that primarily metabolize nicotine. UGT2B10 is the 
primary, if not the only, catalyst of nicotine and cotinine N-glucuronidation (Berg et al., 
2010; Chen et al., 2007). The SNP rs61750900 in particular codes the Asp67Tyr UT2B10 
variant enzyme, a missense mutation. This enzyme significantly reduces nicotine and 
cotinine glucuronidation while also potentially influencing cigarette consumption (Berg et 
al., 2010; Chen et al., 2010). 
 
Table 3-18: Comparison of mSASSS1 values between non-smokers and smokers with 
GG, GT, and TT genotypes for the rs61750900 SNP 
Smoking 
Status 
Genotype Patient Count mSASSS1 P-value 
Non-smoker GG 40 0 ––– 	   GT 3 3.96 0.557 	   TT 1 1.41 0.903 
Smoker GG 26 0 ––– 	   GT 6 -13.23 0.0084 	   TT 0 ––– ––– 
	   
 
 
 
 
 
 
 
 
 
4	  
 
Discussion	  
	   
 
4.1 - Discussion 
 
AS is an inflammatory immune mediated disease that is characterized by neo- 
ossification of the sacroiliac joint and axial spine. Although the etiology of AS is not yet 
fully elucidated, there is substantive evidence for the role of genetic, immunological and 
environmental factors in AS pathogenesis. AS exhibits the strongest genetic contribution 
of any complex rheumatic disease. It is associated with the highest relative sibling risk 
(λ= 50-58) and the strongest genotype relative risk (HLA-B*27). Over the last five years, 
there has been a plethora of genes identified in AS arising from GWA studies. 
Consequently, GWA studies have greatly enhanced our understanding of AS  
pathogenesis and have identified SNPs within genes that suggest specific 
immunomodulatory pathways affecting innate and acquired immunity. One such genetic 
association is the IL-23/IL-17 pathway, which contributes to AS pathogenesis. Despite  
the large number of genes identified, only one quarter of the genetic contribution to AS 
has been explained. Various explanations are postulated to explain the missing 
heritability: (1) insufficient samples being investigated; (2) rare genetic variants 
implicated in the pathogenesis, especially for familial disease; (3) presence of gene/gene 
or gene/environment interactions; (4) genetic variants other than SNPs contributing 
significantly to the genetics of AS. Other genetic variants that are presently being 
investigated in AS include CNVs, epigenetics, and gene expression profiling, including 
microRNA (miRNA). 
The first research question of this thesis was formulated following a genome-wide 
microarray study of a large multiplex AS family which revealed association of a 
UGT2B17 CNV in affected family members. The association of two copies of  UGT2B17 
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with AS may play a significant role in disease establishment. The deletion-type variant of 
UGT2B17 has previously been associated with osteoporosis (Yang et al., 2008). In 
addition to inflammatory axial pain, several family members exhibited psoriasis, Crohn’s 
disease and anterior uveitis. The UGT2B17 variant association identified in the multiplex 
family was not associated with AS in a larger independent cohort of unrelated AS cases; 
however, the possibility of a genetic association between UGT2B17 and extra-articular 
features was not examined. This gene is thought to encode a key enzyme in the inhibition 
of androgen activity, making it functionally relevant in AS pathogenesis (Uddin et al., 
2013). Given that the functional consequences of a CNV alteration may be greater than 
many single-base pair sequence changes and that CNVs have the potential to significantly 
alter gene expression, a systematic evaluation is warranted. 
In this thesis, a concerted effort was undertaken to interrogate the genetics of 
disease expression rather than disease susceptibility. Much of the effort to date has been 
focused on genetic susceptibility. The genetics of disease susceptibility can often be 
challenging, as numerous genes interacting with unknown environmental factors are 
likely to increase the risk of developing disease. Therefore, it may be more strategic to 
investigate a specific feature of AS, particularly if this is a heritable disease  
manifestation. This endophenotype-based approach has the potential to enhance the 
genetic dissection of complex diseases. Endophenotypes may result from a subset of the 
genes necessary to develop AS because only a portion of the disease is being evaluated. 
An endophenotype, by definition, should be heritable and ideally not associated with 
disease activity. In other words, it is primarily state-independent and co-segregates with 
disease within families. The endophenotype should be found in higher frequency in first 
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and second degree relatives that do not have AS, as compared with the general population 
(Lee, Iafrate & Brothman, 2007). All of these attributes exist for psoriasis, IBD and 
uveitis, which are extra-articular features of AS. As noted above, about 30 to 40% of AS 
patients will develop anterior uveitis, 20% will develop psoriasis and 5 to 10% will 
develop inflammatory colitis. GWA studies have demonstrated a link between AS and 
each of these diseases, suggesting that there is likely an underlying factor in AS that 
predisposes the patient to develop related autoimmune diseases. 
CNVs are reported to occur in 12% of the human genome and to contribute 0.12% 
to 7.3% of the genomic variability observed in humans (Scherer et al., 2007). It is 
intriguing that over 41% of all CNVs identified overlap with known genes. By extension, 
CNVs may play a prominent role in modulating genetic expression (Alkan, Coe & 
Eichler, 2011; Jung et al., 2014; Tsui et al., 2014; Uddin, et al., 2014; Wang et al., 2015). 
CNVs contribute to phenotypic expression by several molecular mechanisms. One of the 
most commonly recognized mechanisms for altering phenotype is attributed to dosage- 
sensitive genes, known as the “dosage effect” (Lupski et al., 1992). CNVs also have a 
“position effect,” wherein gene expression can be altered depending on CNV 
chromosomal location, which can often be translocated (Kleinjan & van Hayningen, 
2005). Another molecular mechanism by which rearrangements of the genome may alter 
disease phenotype is the unmasking of recessive mutations or functional polymorphisms 
of the remaining allele when a deletion occurs (Kurotaki et al., 2005). 
GWA studies have been successful on several occasions in exploring AS 
associated CNVs. One study, in particular, by Jung et al. reported a significant association 
between 8  CNVs  regions  (i.e.,  1p34.2,  1q32.2,  2q31.2,  6p21.32,  11q22.1,   13q13.1, 
	   
 
16p13.3, and 22q11.1) and risk of AS. This association remained significant even after 
accommodating for the contribution to AS risk from the well known AS susceptibility 
gene, HLA-B*27 (Jung et al., 2014). The 8 CNV regions identified in that study were near 
genes that have already been established in AS pathogenesis (e.g., HHAT, IL-17RA, 
BMP6, and BMP8A). There was a dose-dependent relationship observed in CNVs of these 
genetic components and an effect on AS presentation. Additional copy numbers in IL- 
17RA and reduction in the copy number in BMP8A were significantly associated with 
diminished disease expression in individuals. CNV deletion in the HHAT gene has been 
demonstrated in the promotion of osteoblastic activity in arthritis leading to joint 
remodelling. Furthermore, a CNV dose-dependent relationship was demonstrated in the 
FCGR3A and FCGR3B genes, specifically suggesting that copy number of 3 or less was 
significantly associated with AS disease presentation (Wang et al., 2015). 
A relatively large cohort of AS patients (n = 896) was investigated to determine 
whether the UGT2B17 CNV was associated with the extra-articular features of AS  
disease expression. We also set out to determine if gene-gene interactions exist between 
UGT2B17 and HLA-B*27. UGT2B17 in copy number 2 was not associated with any of  
the extra-articular features, whether it be uveitis, psoriasis or IBD. No gene-gene 
interaction was noted between UGT2B17 and HLA-B*27. There are multiple reasons why 
an association was not detected. First, it is entirely conceivable and likely that a true 
association does not exist between UGT2B17 and extra-articular manifestations. Although 
our study was not powered to confidently rule out such an association, this represents the 
most likely scenario. Likewise, the sample size is too small to appreciate any contribution 
that UGT2B17 CNV had on expression of extra-articular features or interaction with the 
	   
 
MHC gene in disease expression, despite a true association existing. A larger cohort of 
individuals affected with AS may show significant association of the gene with these 
features. Secondly, the UGT2B17 gene in copy number 2 was associated with AS 
susceptibility in a multiplex family, but no association appears in the general population. 
Therefore, UGT2B17 may be a rare or intermediate variant contributing to the disease 
only in rare multiplex families and not in patients that predominantly have sporadic 
disease. It is also conceivable that UGT2B17 is a population-specific variant in the 
Newfoundland population, but not in outbred Caucasian populations. The Newfoundland 
population is significantly different from populations in other areas of Canada and the 
world due to a founder effect that has resulted in increased signal-to-noise ratio as well as 
greater number and length of runs of homozygosity. The association of this gene with AS 
and extra-articular features may thus be more applicable to the Newfoundland population. 
The second research question of this thesis was formulated following the observation 
that there appeared to be great variability in spinal damage in AS, both in severity 
and disease progression. Radiographic disease severity and progression of the axial 
spine is not linear. Even though the mean radiographic progression was 1.3 mSASSS, 
some patients exhibit a much higher rate of progression. Clinical factors that have 
previously been associated with rapid radiographic progression include baseline 
radiographic damage, elevated acute phase reactants and cigarette smoking (Poddubnyy 
et al., 2012). Smoking has been associated with worse radiographic outcomes in AxSpA – 
a relationship that may be dose-dependent. Smoking has been associated with worse 
inflammation and radiographic damage in early AxSpA. Worsening radiographic severity 
even in longstanding disease has also been observed (Chung, Machado, van der    Heijde, 
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D'Agostino & Dougados, 2012). As a result, we set out to investigate whether there is an 
association between genetic variants related to smoking metabolism and radiographic 
progression in AxSpA. A	  multiple	  linear	  regression	  was	  used	  to	  determine	  the	  association	  between	  each	  SNP	   and	   the	   mean	   values	   of	   mSASSS.	   The	   multiple	   linear	   regression	   models	   were	  controlled	   for	   age,	   gender	   and	   smoking	   habit.	   In	   this	   analysis	   three	   inheritance	  models	   were	   examined:	   additive,	   dominant	   and	   recessive.	   For	   each	   genotype,	   the	  HWE	   was	   tested,	   and	   only	   those	   SNPs	   that	   follow	   the	   HWE	   were	   included.	   An	  interaction	   term	   between	   smoking	   habit	   (“yes”	   versus	   “no”)	   and	   each	   SNP	   was	  introduced	   into	   the	   multiple	   linear	   regression	   models	   to	   examine	   the	   association	  among	   smokers	   and	   non-­‐	   smokers,	   respectively.	   AS	   cohorts	   with	   repeated	  radiographic	   assessments	   that	   also	   have	   DNA	   collected	   is	   quite	   rare.	   From	   our	  knowledge	   to	   date,	   the	  U	   of	   T	   AS	   cohort	   has	   the	   largest	   collection	   of	   patients	  with	  repeated	  radiographic	  measurements.	  Our	  plan	  is	  to	  replicate	  our	  study,	  once	  another	  independent	   AS	   cohort	   has	   been	   established	   at	   University	   of	   Toronto.	   Although	  collection	  for	  additional	  samples	  have	  started,	  this	  will	  take	  some	  time,	  as	  the	  median	  intervals	  between	  radiographics	  is	  3	  years.	  Thus,	  our	  study	  was	  not	  validated	  as	  part	  of	  this	  thesis.	  	  
Disease severity scores (mSASSS) were significantly associated with two SNPs 
from the CHRNA7 gene: rs7178176 (dominant model p-value = 0.0005; genotype p-value 
= 0.001) and rs11071593 (dominant model p-value = 0.0005; genotype p-value = 0.001). 
Radiographic progression was determined to be associated with two distinctly different 
SNPs from CHRNA7: rs2337506 (recessive model p-value < 0.001; genotype p-value = 
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0.0003) and rs12910885 (recessive model p-value < 0.0001; genotype p-value = 0.0001). 
When smoking was introduced as an interaction term, there was no association with 
CHRNA7 SNPs with disease severity or progression; however, there was a significant 
association between the SNP rs61750900 and mSASSS in smokers. Among smokers, 
those with GT genotype in this SNP had significantly lower mSASSS1 than those with 
GG. The SNP rs61750900 is a regulatory region variant found in the UGT2B10 gene, 
which produces one of three enzymes that primarily metabolize nicotine. UGT2B10 is the 
primary, if not the only, catalyst of nicotine and cotinine N-glucuronidation (Berg et al., 
2010; Chen et al., 2007). In particular, it codes the Asp67Tyr UT2B10 variant enzyme, a 
missense mutation. This enzyme significantly reduces nicotine and cotinine 
glucuronidation while also potentially influencing cigarette consumption (Berg et al., 
2010; Chen et al., 2010). Thus, we are not able to postulate that it is smoking that led to 
the worsening radiographic outcomes, as it is conceivable that there is a genetic 
association between CHRNA7 and radiographic severity and progression. CHRNA7 
transcribes the alpha 7 nicotinic acetylcholine receptor (nAChR), which mediates immune 
system responses through its interaction with acetylcholine (ACh; Jonge & Ulloa, 2007). 
ACh activates the cholinergic anti-inflammatory pathway of the innate immune system 
and decreases production of endotoxin-inducible pro-inflammatory cytokines such as 
TNF, IL-1β, IL-6 and IL-18 (Borovikova et al., 2000). CHRNA7 produces the receptor 
that mediates the anti-inflammatory effects of ACh. Given that nicotine is another ligand 
that binds to nAChR, nicotine agonists inhibit the production of cytokines and thus inhibit 
a pro-inflammatory response. 
CHRNA7 plays a pivotal role in the mediation of inflammatory pathways, 
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especially those producing TNF, a prominent cytokine implicated in AS pathogenesis. 
The nAChR has been shown to be represented on the surface of macrophages and to play 
a role in efferent vagal anti-inflammatory activity (Pavlov, Wang, Czura, Friedman & 
Tracey, 2003). A recent study to investigate α7nAChR expression on macrophages 
suggests that the α7 subunit on the macrophage is necessary for the suppression of TNF- 
involvement in the cholinergic anti-inflammatory pathway (Wang et al., 2003). The same 
study determined that the inhibition of the α7nAChR in the presence of nicotine was 
successful in restoring TNF production. The significance of the α7 subunit in mediating 
cholinergic anti-inflammatory activity is reinforced through the investigation of α7 
subunit-deficient mice. By releasing increased amounts of TNF, IL-1 and IL-6 into the 
serum from macrophages, gene knockout mice have an increased sensitivity to pro- 
inflammatory stimuli as compared to wild-type mice (Pavlov et al., 2003; Wang et al., 
2003). Additionally, the macrophages of these gene knockout mice did not cease TNF 
production in the presence of nicotine and ACh, further suggesting that α7nAChR 
presentation on macrophages is critical in the inflammatory pathway. 
Contradictory responses have been observed in inflammatory disease progression 
with the introduction of nicotine through smoking. The suggestion that nicotine could be 
an appropriate treatment for some inflammatory diseases was made through a number of 
clinical trials that implicate transdermal nicotine as a potentially successful treatment for 
active UC, an inflammatory disease that has genetic overlap with AS (Jonge & Ulloa, 
2007). While nicotine appears to silence the inflammatory effects of acute UC, it has no 
therapeutic effect in the inflammatory process of Crohn’s disease. The difference between 
the two IBD responses to nicotine may be attributed to different pathogenic effects, 
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different macrophage responses or different response mechanisms to anticholinergic 
affects associated with the nAChR. Regardless of the exact mechanism, these two co- 
familial diseases appear to have different responses to nicotine agonists via the nAChR. 
Other inflammatory diseases, namely arthritis, appear to exhibit variable responses to 
nicotine as well. The introduction of nicotine seems to enhance an individual’s 
susceptibility to rheumatoid arthritis while decreasing their risk of osteoarthritis 
(Papadopoulos et al., 2005). The nAChR may be susceptible to a variety of different 
mutations or deletions across inflammatory diseases that alter the binding capacity for 
ACh or nicotine. Variability in disease response to nicotine is apparent when comparing 
smoking versus non-smoking cases. Our study revealed an association between AS 
mSASSS score, disease progression and the CHRNA7 gene that is responsible for the 
nAChR production; however, unlike UC, which seems to express improved disease 
outcomes with the introduction of nicotine, smoking has been observed to worsen disease 
outcomes in AS patients. As was previously discussed, more rapid progression and 
worsened outcomes have been observed in AS disease activity and radiographic 
progression in affected individuals who smoke (Kaan & Ferda, 2005; Mattey et al., 2011; 
Poddubnyy et al., 2012). 
An alternative proposal is that the disease progression of AS is not strictly the 
result of an inflammatory response. AS is an inflammatory disease that is primarily 
characterized by the formation of new bone. Radiographic progression and the formation 
of new spinal syndesmophytes is, in part, an inflammatory process. Thus it’s expected  
that a gene, such as CHRNA7, primarily involved in inflammation and cytokine release 
would be chiefly responsible for new bone formation. The initial inflammatory 
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presentation peripherally at the site of entheses and axially at the site of new bone 
proliferation is essential for triggering the progression of the disease; however, the rate at 
which new bone forms to produce radiographic changes and sydesmophytes does not 
appear to be simply a product of the inflammatory response (Slobodin, Rosner & Odeh, 
2013). The exact mechanism behind the radiographic progression of AS thus remains 
unknown. This suggests that there may be an alternative mechanism of disease 
progression beyond the effects of the initial points of inflammation. An unknown facet 
may participate in the interaction with nicotine to hasten radiographic progression; 
however, we did not find any credible link between CHRNA7 and new bone formation. There	   are	   several	   limitations	   in	   this	   study	   that	   should	   be	   considered	   when	  interpreting	   the	   results.	   First,	   some	   of	   the	   clinical	   variables,	   such	   as	   IBD,	   psoriasis,	  uveitis	  and	  smoking	  history,	  were	  self-­‐reported	  by	  the	  patient.	  A	  rheumatologist	  did	  not	   always	   diagnose	   the	   presence	   of	   extra-­‐articular	   features	   at	   the	   time	   of	   clinical	  interview	  (e.g.,	  a	  history	  of	  ever	  having	  the	  condition	  was	  recorded	  only	  if	  the	  patient	  reported	   it).	   A	   rheumatologist	   was	   thus	   unable	   to	   independently	   diagnose	   the	  comorbidities	  in	  all	  cases	  when	  a	  disease	  was	  treated	  and	  not	  present	  at	  the	  time	  of	  data	  collection.	  However	  we	  confident	   in	  our	  reporting	  as	   in	  the	  SPAARCC	  protocol,	  the	  presence	  of	  extra-­‐articular	  features	  was	  determined	  by	  asking	  that	  patient	  about	  symptoms	   of	   IBD,	   uveitis	   or	   psoriasis.	   Once	   the	   patient	   stated	   they	   had	   symptoms	  compatible	  with	   these	   symptoms,	   they	  were	   asked	   if	   the	   diagnosis	  was	  made	   by	   a	  specialist	   (i.e.	   gastroenterologist	   for	   IBD,	   ophthalmologist	   for	   uveitis	   and	  dermatologist	   for	   psoriasis).	   Only	   if	   the	   diagnosis	   of	   IBD	   was	   made	   by	   a	  gastroenterologist	   ,	  would	   this	  be	  counted	   in	   the	  database.	  As	  a	   result	  we	  are	   fairly	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confident	  about	  our	  diagnosis.	  Also	  our	  prevalence	  of	  extra-­‐articular	  features	  for	  our	  cohort	  is	  in	  keeping	  with	  previously	  published	  rates.	  	  Treatment	   history	   could	   have	   also	   confounded	   the	   presence	   or	   absence	   of	  comorbidities.	  How	  treatment	  might	  have	  altered	  disease	  progression	  was	  not	  taken	  into	  account	  for	  this	  study,	  so	  we	  can	  neither	  confirm	  nor	  rule	  out	  that	  medications	  played	   a	   role	   in	   pathogenesis.	   This	   is	   especially	   true	   for	   systemic	   medications.	  Treatments	   such	   as	   biological	   agents	   for	   AS	   could	   conceal	   the	   presence	   of	   other	  inflammatory	   diseases	   thus	   decreasing	   the	   possibility	   of	   IBD,	   psoriasis,	   or	   uveitis	  presentation.	  Medications	  could	  also	  reduce	   the	  possibility	  of	  developing	  one	  of	   the	  AS	   comorbidities	   despite	   a	   genetic	   and/or	   environmental	   predisposition	   to	   the	  condition.	  When	  our	  study	  was	  conducted	  there	  were	  two	  classes	  of	  treatment:	  anti-­‐inflammatory	   agents	   and	   TNF	   inhibitors.	   The	   TNF	   inhibitors	   were	   used	   by	  approximately	   25%	   of	   the	   patients.	   The	   remaining	  majority	   of	   patients	   used	   anut-­‐	  inflammatory	   agents.	   The	   use	   of	   anti-­‐inflammatory	   agents	   will	   not	   alter	   the	  development	   of	   extra-­‐articular	   features	   but	   the	   biologic	   agents	   may	   affect	   the	  presentation	  of	  the	  features.	  This	  is	  because	  TNF	  monoclonal	  antibodies	  are	  effective	  in	   treating	  psoriasis,	   IBD	   and	  uveitis.	  Meanwhile	  TNF	   receptor	   antagonists,	   such	   as	  Etanercept,	  are	  effective	  in	  treating	  psoriasis.	   	  As	  TNF	  agents	  were	  being	  used	  many	  years	  after	  the	  onset	  of	  the	  disease,	  a	  large	  number	  of	  patients	  had	  already	  developed	  their	   extra-­‐articular	   features.	   The	   frequency	   of	   extra-­‐articular	   features	   in	   our	  population	  is	  within	  the	  range	  of	  what	  has	  been	  reported	  in	  the	  literature.	  Thus	  it	  is	  possible	   that	   we	   may	   have	   masked	   extra-­‐articular	   features	   in	   a	   subset	   of	   patients	  receiving	   TNF-­‐	   inhibitors,	   but	   the	   effect	   of	   this	   was	   likely	  minimal.	   	   Regarding	   the	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second	   part	   of	   the	   study,	   continuous	   NSAID	   use	   only	   marginally	   affects	   disease	  progression	  and	  despite	  the	  effectiveness	  of	  TNF	  inhibitors	  in	  treating	  extra-­‐articular	  symptoms,	   the	   pivotal	   clinical	   trails	   have	   failed	   to	   show	   a	   delaying	   of	   radiographic	  progression.	   Many	   long	   term	   studies,	   such	   as	   the	   recent	   study	   from	   the	   OSKAR	  database,	  have	  also	  failed	  to	  show	  alternation	  of	  the	  mSASS	  scores	  with	  as	  long	  as	  five	  years	  of	  TNF	  inhibitor	  therapy	  (Kim	  et	  al.,	  2016).	  Thus	  we	  do	  not	  think	  treatment	  of	  TNF-­‐	  inhibitors	  for	  a	  median	  of	  three	  years	  –	  as	  in	  our	  study	  –	  greatly	  influenced	  the	  radiographic	  progression	  in	  the	  majority	  of	  the	  patients.	  	  
There may have been recall bias with smoking history that resulted in an exposure 
misclassification. The patient reported smoking history if they had ever smoked, not if 
they were a smoker at the time of clinical examination. It is possible that a patient could 
have misreported smoking history for any number of reasons. For the purposes of this 
study, we used a positive or negative history of smoking in the analysis, not a detailed 
pack-year history. This limited our ability to determine if there was a dose-dependent 
relationship between mSASS scores and smoking history. 
 
Limitations in study design may have also affected results. A blind assessment 
was not performed: rheumatologists ascertained patient information in a clinical setting 
and not in a controlled trial setting. As a result, there may be researcher bias, especially in 
the reporting of the radiographs for mSASS scores. Another	   limitation	   regarding	   the	   analysis	   portion	   of	   this	   study	   stems	   from	  inconsistencies	  in	  recording	  clinical	  patient	  information.	  Phenotypic	  information	  was	  not	   collected	   for	   all	   896	   patients	   despite	   complete	   genotyping.	   Varying	   amounts	   of	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information	  were	  missing	   from	   IBD,	   psoriasis,	   uveitis	   and	  HLA-­‐B*27	  status	   causing	  there	  to	  be	  smaller	  sample	  sizes	  for	  some	  Fisher’s	  exact	  tests	  –	  psoriasis	  in	  particular.	  SPARRC	   was	   designed	   as	   a	   real	   world	   prospective	   cohort.	   Relevant	   clinical	   and	  disease	  information	  was	  collected	  by	  participating	  sites	  during	  routine	  clinical	  visits.	  It	  was	  obtained	  over	  many	  years	  by	  rheumatology	  fellows	  and	  rheumatologists.	  Most	  clinicians	  received	  a	  few	  training	  sessions	  regarding	  the	  variables	  being	  collected,	  and	  this	  helped	  standardize	  the	  process.	  At	  times	  during	  clinic	  visit,	  physicians	  were	  short	  of	   time,	   and	   under	   these	   circumstances,	   the	   data	   was	   not	   systematically	   collected.	  Also	   it	   has	   been	   our	   experience,	   that	   some	   physicians	   appear	   to	   transcribe	   only	  positive	  attributes,	  and	  would	  leave	  the	  assessment	  blank	  if	  the	  event	  did	  not	  occur.	  This	  created	  a	  difficult	  situation	  –	  as	  we	  were	  not	  sure	  if	  these	  patients	  were	  negative	  for	  the	  extra-­‐articular	  feature	  or	  if	  the	  assessment	  was	  missed.	  It	  was	  for	  this	  reason	  these	   patients	  were	   not	   included	   in	   the	   assessment.	   In	   addition,	   although	   a	   central	  protocol	  was	  used,	  each	  site	  had	  it	  own	  area	  of	   interest	  and	  this	  resulted	  in	  various	  parts	   of	   the	   protocol	   being	  more	   adhered	   to	   by	   certain	   sites.	   	   The	   clinical	   data	   in	  Alberta	  was	  collected	  by	  a	  large	  network	  of	  physicians	  who	  were	  capturing	  the	  data	  and	   then	   sending	   the	   patient	   to	  University	   of	   Alberta.	   The	   primary	   interest	   for	   the	  university	  was	  the	  development	  of	  a	  MRI	  and	  radiographic	  scoring	  system.	  University	  of	  Toronto	  had	  the	  most	  through	  clinical	  assessments	  and	  data	  collection.	  	  They	  were	  able	   to	   bring	   their	   patients	   back	   in	   a	   more	   regular	   fashion	   and	   had	   data	   entry	  personal	  working	  closely	  with	  the	  clinicians.	  The	  Newfoundland	  site	  was	  the	  smallest	  of	   the	   three	   core	   sites	   and	   focused	  exclusively	  on	  genetics.	   Follow	  up	  was	   sporadic	  due	   to	   the	   volume	   of	   urgent	   patients	   that	   need	   to	   be	   seen	   by	   a	   limited	   number	   of	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rheumatologists.	  It	  would	  have	  been	  ideal	  to	  have	  more	  detailed	  data	  about	  smoking.	  	  Categorizing	   smokers	   as	   never,	   past,	   and	   current	   with	   the	   addition	   of	   pack	   year	  history	   would	   have	   beneficial	   for	   our	   analysis.	   Unfortunately,	   the	   importance	   of	  capturing	   detailed	   smoking	   information	   was	   not	   appreciated	   when	   the	   SPARCC	  protocol	  was	  initially	  rolled	  out	  and	  pack	  year	  history	  was	  not	  consistently	  available	  for	   each	   patient.	   This	   missing	   data	   may	   have	   had	   some	   bearing	   on	   the	   level	   of	  significance.	  However,	   to	  date	   the	   clinical	   data	   of	   those	  with	  missing	  data	  does	  not	  appear	  to	  be	  different	  from	  those	  with	  a	  complete	  set	  of	  clinical	  data.	  	  
Additionally, this study represented an association-based analysis. Though association 
studies are the analysis of choice for a cohort of unrelated individuals, like the one used in 
this thesis, there are characteristics that cause restriction in the understanding of our 
findings. Specifically, significant results only represent an observation of co- occurrence 
between alleles and phenotypes, not a causal relationship. High rates of false positive 
associations, false negative associations and a true association that is population- specific 
(i.e., relatively rare) are contributing factors in impeding the replication of the results 
from association analysis studies. Also, multiple testing should be accounted for in the 
case of an allele not being independent of LD. It is difficult to discern if an association 
study is successfully replicated because the SNP under study is a causative agent to the 
disease, or if the SNP is in a LD with the authentic disease mutation. As a result, there is a 
high frequency of false positive results in association analyses. The power of   association 
studies is another important factor as underpowered studies may result in false negative 
findings. Our multiple linear regression analyses contained 76 patients, only half of which 
were smokers. This sample size may not be large enough to appreciate the true effects of 
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environmental factors with genetic interactions and smoking. With such a small sample 
size it is difficult to distinguish whether the genetic factors alone impacted disease 
severity and progression or if the interaction of smoking with the genes played a role in 
worsening severity and more rapid progression. 
 
 
4.2 - Conclusion 
 
The results of this study suggested that the UGT2B17 gene found to be associated 
with AS in copy number 2 in a multiplex family was not significantly associated with the 
extra-articular features of AS, nor was it significantly associated with HLA-B*27. It 
appears unlikely that AS heritability stems from a gene-gene interaction between 
UGT2B17 and HLA-B*27; however, there is the potential that a portion of the missing 
heritability of AS can be explained through UGT2B17 as a rare variant. The recent 
identification of SEC16A and MAMDC4 suggests that this is a plausible interpretation. 
Future studies could investigate UGT2B17 as a rare variant using exome sequencing. 
This study also identified that mSASSS score and disease progression were each 
significantly associated with two SNPs located within CHRNA7, a gene implicated in the 
mediation of inflammatory responses and the production of TNF. This finding suggests 
that smoking may interact with the receptor product of this gene to exacerbate the 
inflammatory response; however, interaction with smoking, genetic variants related to 
nicotine metabolism and ankylosis is not clearly demonstrated in this study. Collectively, 
the results of this study make a convincing argument to continue this research. 
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Appendix	  1:	  
 
Additional	  Gene	  Variants	  Identified	  via	  
GWAS	  
	  	  
 
 
Intergenic Regions 
 
The intergenic regions at chromosomes 2p15 and 21q22 have been found to be 
susceptible loci for the disease in multiple different AS cohorts. The chromosomal region 
21q22 has also been previously identified as containing loci eliciting pediatric IBD 
susceptibility. The occurrence of IBD as a comorbidity of AS indicates that the 
inflammatory mechanisms in both diseases might be similar. The previously identified 
common genetic factors in both diseases provide convincing evidence that the intergenic 
regions found have potential action in disease susceptibility (Kugathasan et al., 2008; 
Reveille, 2012). The combined influence of these regions explains 0.575% of the 
heritability of AS (Brown, 2011; Reveille, 2012). 
 
 
IL-1 Region Genes and IL1R2 
 
The locus IL-1 is found at chromosome 2p15 and within this region lies IL1R2 at 
2p12 (Reveille, 2012). The gene product is the IL-1 receptor type 2 (IL1R2), which acts  
to bind IL-1, preventing its binding to IL1R1. When IL-1 binds, its activity is repressed. 
IL-1 cytokines have action in producing inflammatory responses (Reveille, 2011). IL1R2 
may have a relationship with ERAP1, a gene previously mentioned to be related to AS 
susceptibility. ERAP1 has a potential role in the cleavage of the IL1R2 product from the 
cell membrane. It regulates the function of IL1R2 by decreasing its expression. ERAP1 
thus inhibits the binding of the IL1R2 product to IL-1, allowing for IL-1 to produce an 
inflammatory effect (Reveille, 2011). IL1R2 has very little influence in accounting for AS 
heritability as it is only responsible for 0.12% of the variation (Brown, 2011; Reveille, 
2012). 
	  	  
 
 
 
 
TNF Pathway Associated Genes 
 
AS is associated with three genes involved in the TNF pathway. LTBR and 
TNFRSF1A are found on the same chromosome, 12p13, and account for 0.075% of AS 
heritability (Brown, 2011; Reveille, 2012). TNFRSF1A has previously been associated 
with IBD (Reveille, 2012). This overlap between comorbid diseases supports the 
conjecture that TNFRSF1A is associated with inflammation pathways common to both 
conditions. Additionally, mice studies have indicated a potential link between TNFRSF1A 
and the development of sacroiliitis, a feature of AS pathogenesis (Kenna, Davidson & 
Thomas, 2011). A relationship between TNFRSF1A and ERAP1 has been proposed as 
ERAP1 is responsible for cleavage of TNFR1 from the cell surface, which aids in 
regulating the optimal function of TNFRSF1A (Davidson et al., 2011; TASC, 2012). 
TBKBP1, a gene located on chromosome 17q21, is a susceptible loci for AS 
pathogenesis, accounting for 0.054% of AS heritability (Reveille, 2012; TASC & 
WTCCC2, 2011). TBKBP1 differs in genotype frequencies between AS cases and healthy 
controls (Lian et al., 2013). 
 
 
ANTXR2	  
 
ANTXR2 is located on chromosome 4q21 and its expression codes for the protein 
capillary morphogenesis protein-2. It accounts for 0.054% of AS heritability (Brown, 
2011; Reveille, 2012). The gene is suspected to be involved in extracellular matrix 
adhesion  as  its  protein  has  been  observed  to  bind  to  type  IV  collagen  and laminin. 
	  	  
 
 
Although ANTXR2 has been associated with AS in GWAS studies, its role in disease 
pathogenesis remains largely unknown (Reveille, 2011). 
 
 
PTGER46	  
 
PTGER46 has been associated with AS disease pathogenesis (IGAS, 2013). It is 
responsible for approximately 0.052% of AS heritability (Brown, 2011; Reveille, 2012). 
PTGER46 is expressed in the presence of mechanical stress and results in a protein 
product called prostaglandin E2. This protein initiates the production of IL-23 by the 
dendritic cells, which subsequently commences the IL17-IL23 pathway that results in an 
inflammatory response. Additionally, prostaglandin E2 causes bone formation, a primary 
characteristic of AS pathogenesis (Reveille, 2012). 
 
 
KIF21B	  
 
KIF21B, located on chromosome 1q23, was identified in a study of Crohn’s 
disease-associated genetic regions in individuals with AS (Reveille, 2012). The gene 
belongs to the family encoding kinesin motor proteins, which are responsible for the 
transport of components along microtubules. KIF21B is not the only gene from  this 
family encoding kinesin motor proteins to be associated with arthritis or autoimmune 
disorders. KIF5A has been associated with rheumatoid arthritis and type 1 diabetes 
susceptibility (TASC & SPARCC, 2010). The loci associated with the autoimmune 
disorder multiple sclerosis is also located near KIF5A. This association of functional  
genes with autoimmune disorders supports the role of KIF21B in AS susceptibility. The 
	  	  
 
 
gene was found to be associated with the disease, contributing about 0.25% to the overall 
heritability of AS (Brown, 2011; Reveille, 2012). 
 
 
EOMES	  
 
EOMES encodes a transcription factor called eomesodermin, which is expressed  
in the presence of RUNX3, another gene protein associated with AS. Together, EOMES 
and RUNX3 mediate cell differentiation of CD8+ T cells (IGAS, 2013; Pearce et al., 
2003). 
 
 
ZMIZ1	  
 
Zinc finger MIZ domain-containing protein 1 (ZMIZ1) is a coactivator of an 
inhibitory protein that affects the CD8+ T cell count through STAT-mediated cytokine 
signaling. It is not certain whether AS pathogenesis is directly affected by the alteration  
of CD8+ T cell count by ZMIZ1 (IGAS, 2013). 
 
 
IL7R	    
 
IL7R is a gene associated with AS; its protein product alters CD8+ T cell counts. 
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The gene was found to be a risk variant for AS in combination with low CD8+ T cell 
counts (IGAS, 2013). 
 
 
BACH2	  
 
Transcription regulator protein BACH2 has a complex effect on B cell 
differentiation and function, which elicits a response in the CD4+  T cell counts. Theeffects 
of BACH2 transcription factor thus indirectly alter CD4+ T lymphocyte count (IGAS, 
2013; Muto et al., 2010). 
 
 
SH2B3	  
 
SH2B3 is a leukocyte adaptor protein that has an established effect on CD4+ T cell 
counts in AS patients. The gene product of SH2B3 is involved in T cell receptor  
signaling, which facilitates the conversion of CD8+ T cells to cytotoxic or Th cells 
(Huang, Li, Tanaka, Moore & Hayashi, 1995; IGAS, 2013). 
 
 
GPR35,	  GPR37	  and	  GPR65	  
 
The functions of the genes GPR35, GPR37, and GPR65 are not very well 
understood. The study by IGAS (2013) found these loci to be associated with risk of AS. 
GPR35, GPR37 and GPR65 are G protein-coupled receptor coding loci. GPR65 is also 
associated with Crohn’s disease. Very little is known about the function of these loci in 
the pro-inflammatory process of either disease (IGAS, 2013). 
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HLA-­‐A*0201	  
 
HLA-A*02 is a MHC gene found to be associated with AS. Previously, this locus 
had been associated with anterior uveitis, a common extra-articular feature of AS (IGAS, 
2013; Khan, Kushner & Braun, 1981). 
 
 
FCGR2A	  
 
Fc fragment of IgG, low affinity IIa, receptor gene (FCGR2A) was found to be 
significantly associated with AS disease risk (IGAS, 2013). This gene has known function 
in coding a protein that is a cell surface receptor found on phagocytic cells. It is involved 
in immunological processes, mainly the clearance of immune complexes (Franke et al., 
2015). 
 
 
UBE2E3	  
 
Ubiquitin-conjugating enzyme E2E 3 (UBE2E3) is significantly associated with 
AS pathogenesis (IGAS, 2013). Ubiquitination is an important mechanism for targeting 
protein degradation. This gene is highly conserved in eukaryotes, encoding a member of 
the E2 ubiquitin-conjugating enzyme family. It has known function in conjugating 
proteins using ubiquitin (Plafker & Plafker, 2015). 
 
 
NOS2	  
 
Nitric oxide synthase 2 (NOS2) is a gene found on chromosome 17. It is inducible 
by lipopolysaccharides and certain cytokines (NCBI, 2015b). This gene, which encodes 
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nitric oxide synthase, is expressed in the liver and contributes to AS heritability (IGAS, 
2013). 
 
 
NKX2-­‐3	  
 
NK2 homeobox 3 (NKX2-3) encodes a protein belonging to the NKX family of 
homeo-domain transcription (IGAS, 2013; NCBI, 2015a). 
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Appendix	  2:	  
 
Results	  Displaying	  Inheritance	  Models	  
(Dominant,	  Recessive	  &	  Additive)	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Table	   A-­‐1:	   Interaction	   between	   selected	   genetic	   variants,	   radiographic	   severity	  (mSASSS)	  and	  both	  smoking	  status	  and	  sex.	  Three	  inheritance	  models	  are	  described	  as	  Dominant	  (CC	  or	  CT),	  Recessive	  (TT),	  and	  Additive	  	  	  
SNP	   Interaction	   between	  
selected	   genetic	  
variants,	   radiographic	  
severity	   (mSASSS)	   and	  
smoking	  status	  
Interaction	  	  	  	  	  	  	  	  	  	  between	  
selected	   genetic	  
variants,	   radiographic	  
severity	   (mSASSS)	   and	  
sex	  
rs885071	   	   	  	   Additive	   0.5209	   0.776	  Recessive	   0.6174	   0.8496	  Dominant	   NA	   NA	  Genotype	   0.7068	   0.893	  
rs1800925	   	   	  	   Additive	   0.6468	   0.1621	  Recessive	   0.938	   0.2271	  Dominant	   NA	   NA	  Genotype	   0.7014	   0.2991	  
rs2337506	   	   	  	   Additive	   0.5814	   0.6825	  Recessive	   0.8124	   0.6267	  Dominant	   0.448	   0.8346	  Genotype	   0.686	   0.8864	  
rs4779565	   	   	  	   Additive	   0.3959	   0.8642	  Recessive	   0.4022	   0.9115	  Dominant	   0.5928	   0.8824	  Genotype	   0.6555	   0.9838	  
rs4779978	   	   	  	   Additive	   0.0314	   0.3307	  Recessive	   0.0037	   0.2689	  Dominant	   0.4865	   0.6001	  Genotype	   0.0127	   0.5371	  
rs6494223	   	   	  	   Additive	   0.6342	   0.5938	  Recessive	   0.7717	   0.5131	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   Dominant	   0.4526	   0.7031	  Genotype	   0.7401	   0.7823	  
rs7167551	   	   	  	   Additive	   0.8761	   0.8983	  Recessive	   NA	   NA	  Dominant	   0.9237	   0.9605	  Genotype	   0.9237	   NA	  
rs7178176	   	   	  	   Additive	   0.315	   0.5947	  Recessive	   0.2194	   0.3625	  Dominant	   0.6909	   0.6909	  Genotype	   0.5443	   0.4092	  
rs11071593	   	   	  	   Additive	   0.1642	   0.3701	  Recessive	   0.279	   0.5007	  Dominant	   NA	   NA	  Genotype	   0.8752	   0.9793	  
rs11636680	   	   	  	   Additive	   0.4023	   0.7161	  Recessive	   0.5847	   0.7221	  Dominant	   0.3282	   0.9383	  Genotype	   0.592	   0.9437	  
rs12910885	   	   	  	   Additive	   0.5814	   0.6825	  Recessive	   0.8124	   0.6267	  Dominant	   0.448	   0.8346	  Genotype	   0.686	   0.8864	  
rs12916879	   	   	  	   Additive	   0.1374	   0.325	  Recessive	   0.4427	   0.107	  Dominant	   0.0846	   0.8222	  Genotype	   0.2175	   0.2319	  
rs13329490	   	   	  	   Additive	   0.5061	   0.5103	  Recessive	   0.3321	   0.4394	  Dominant	   NA	   NA	  Genotype	   0.2391	   0.4007	  
rs60109258	   	   	  	   Additive	   0.4789	   0.5439	  Recessive	   0.7532	   0.5223	  Dominant	   0.166	   0.5428	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   Genotype	   0.3761	   0.7092	  
rs61750900	   	   	  	   Additive	   0.0251	   0.2589	  Recessive	   0.0351	   0.4407	  Dominant	   NA	   NA	  Genotype	   0.0435	   0.6313	  
rs62003625	   	   	  	   Additive	   0.3928	   0.8655	  Recessive	   0.4316	   0.8978	  Dominant	   NA	   NA	  Genotype	   0.5468	   0.9363	  
rs113629315	   	   	  	   Genotype	   0.6482	   0.6234	  
 
 
 
 
Table	   A-­‐2:	  Interaction	  between	  selected	  genetic	  variants,	  radiographic	  progression	  (change	   in	   mSASSS/time)	   and	   both	   smoking	   status	   and	   sex.	   Three	   inheritance	  models	  are	  described	  as	  Dominant	  (CC	  or	  CT),	  Recessive	  (TT),	  and	  Additive	  	   	  	  	  	  	  
SNP	  
Interaction	   between	  
selected	   genetic	  
variants,	   radiographic	  
progression	   (change	   in	  
mSASSS/time)	   	   and	  
smoking	  status	  
	  
Interaction	  	  	  	  	  	  	  	  	  	  between	  
selected	   genetic	  
variants,	   radiographic	  
progression	   (Change	   in	  
mSASSS/time)	  and	  sex	  
rs885071	   	   	  	   Additive	   0.7068	   0.6175	  Recessive	   0.3977	   0.4735	  Dominant	   NA	   NA	  Genotype	   0.5936	   0.3719	  
rs1800925	   	   	  	   Additive	   0.0261	   0.6428	  Recessive	   0.0607	   0.8631	  Dominant	   NA	   NA	  Genotype	   0.1493	   0.9572	  
rs2337506	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   Additive	   0.215	   0.4385	  Recessive	   0.4656	   0.7092	  Dominant	   0.2896	   0.22	  Genotype	   0.5652	   0.2218	  
rs4779565	   	   	  	   Additive	   0.6439	   0.964	  Recessive	   0.6749	   0.9882	  Dominant	   0.8315	   0.9854	  Genotype	   0.9462	   0.9991	  
rs4779978	   	   	  	   Additive	   0.1182	   0.4517	  Recessive	   0.1831	   0.6298	  Dominant	   0.2218	   0.5369	  Genotype	   0.3521	   0.7992	  
rs6494223	   	   	  	   Additive	   0.4074	   0.7013	  Recessive	   0.6028	   0.9734	  Dominant	   0.5781	   0.7205	  Genotype	   0.8224	   0.9382	  
rs7167551	   	   	  	   Additive	   0.5866	   0.6192	  Recessive	   NA	   NA	  Dominant	   0.5633	   0.376	  Genotype	   0.4022	   NA	  
rs7178176	   	   	  	   Additive	   0.1812	   0.6501	  Recessive	   0.2541	   0.9267	  Dominant	   0.1918	   0.1918	  Genotype	   0.3499	   0.33	  
rs11071593	   	   	  	   Additive	   0.1028	   0.9347	  Recessive	   0.0591	   0.9042	  Dominant	   NA	   NA	  Genotype	   0.1144	   0.8648	  
rs11636680	   	   	  	   Additive	   0.247	   0.7253	  Recessive	   0.597	   0.9399	  Dominant	   0.0672	   0.3007	  Genotype	   0.184	   0.5848	  
rs12910885	   	   	  	   Additive	   0.215	   0.4385	  
	  105	   
 	   Recessive	   0.4656	   0.7092	  Dominant	   0.2896	   0.22	  Genotype	   0.5652	   0.2218	  
rs12916879	   	   	  	   Additive	   0.1258	   0.7632	  Recessive	   0.2246	   0.6736	  Dominant	   0.1673	   0.7419	  Genotype	   0.2824	   0.8	  
rs13329490	   	   	  	   Additive	   0.3508	   0.8099	  Recessive	   0.448	   0.9149	  Dominant	   NA	   NA	  Genotype	   0.5582	   0.9888	  
rs60109258	   	   	  	   Additive	   0.3083	   0.6357	  Recessive	   0.63	   0.962	  Dominant	   0.3775	   0.6365	  Genotype	   0.6555	   0.9042	  
rs61750900	   	   	  	   Additive	   0.44	   0.4582	  Recessive	   0.5685	   0.6227	  Dominant	   NA	   NA	  Genotype	   0.662	   0.7772	  
rs62003625	   	   	  	   Additive	   0.5899	   0.8054	  Recessive	   0.6792	   0.7672	  Dominant	   NA	   NA	  Genotype	   0.7252	   0.7536	  
rs113629315	   	   	  	   Genotype	   0.1655	   0.8443	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Table	  A-­‐3:	  Three inheritance models (additive, dominant and recessive) examined to 
determinate the association between each SNP and the mean values of mSASS1 and 
progression, respectively, in multiple linear regression analysis controlling for age, 
gender and smoking habit. 
 
SNP	   mSASSS1	   progression	  
rs885071	   	   	  	   Additive	   0.9861	   0.3039	  Recessive	   0.8341	   0.5773	  Dominant	   0.4204	   0.0219	  Genotype	   0.6801	   0.071	  
rs1800925	   	   	  	   Additive	   0.8464	   0.7776	  Recessive	   0.7993	   0.4084	  Dominant	   0.1621	   0.142	  Genotype	   0.2936	   0.1384	  
rs2337506	   	   	  	   Additive	   0.4204	   0.0205	  Recessive	   0.0868	   <0.0001	  Dominant	   0.9146	   0.3932	  Genotype	   0.2068	   0.0003	  
rs4779565	   	   	  	   Additive	   0.5638	   0.9576	  Recessive	   0.6333	   0.7391	  Dominant	   0.6226	   0.6138	  Genotype	   0.8455	   0.7416	  
rs4779978	   	   	  	   Additive	   0.2668	   0.074	  Recessive	   0.2008	   0.3457	  Dominant	   0.6232	   0.034	  Genotype	   0.441	   0.1038	  
rs6494223	   	   	  	   Additive	   0.4618	   0.2239	  Recessive	   0.3078	   0.089	  Dominant	   0.9161	   0.8714	  Genotype	   0.5751	   0.2132	  
rs7167551	   	   	  	   Additive	   0.5484	   0.1544	  
	  	  
 
 	   Recessive	   0.8022	   0.2164	  Dominant	   0.5408	   0.222	  Genotype	   0.8284	   0.3206	  
rs7178176	   	   	  	   Additive	   0.0013	   0.0738	  Recessive	   0.0212	   0.125	  Dominant	   0.0005	   0.1527	  Genotype	   0.001	   0.1913	  
rs11071593	   	   	  	   Additive	   0.0319	   0.0465	  Recessive	   0.1717	   0.0878	  Dominant	   0.0023	   0.099	  Genotype	   0.0087	   0.1155	  
rs11636680	   	   	  	   Additive	   0.7277	   0.2094	  Recessive	   0.6034	   0.7556	  Dominant	   0.9245	   0.0258	  Genotype	   0.8427	   0.0771	  
rs12910885	   	   	  	   Additive	   0.4204	   0.0205	  Recessive	   0.0868	   <0.001	  Dominant	   0.9146	   0.3932	  Genotype	   0.2068	   0.0003	  
rs12916879	   	   	  	   Additive	   0.9904	   0.2643	  Recessive	   0.7956	   0.0407	  Dominant	   0.7829	   0.717	  Genotype	   0.8982	   0.0648	  
rs13329490	   	   	  	   Additive	   0.7335	   0.6568	  Recessive	   0.6272	   0.4966	  Dominant	   0.8646	   0.7415	  Genotype	   0.8343	   0.6645	  
rs60109258	   	   	  	   Additive	   0.545	   0.1735	  Recessive	   0.2875	   0.0782	  Dominant	   0.8309	   0.7554	  Genotype	   0.4716	   0.2028	  
rs61750900	   	   	  	   Additive	   0.1779	   0.3658	  Recessive	   0.1142	   0.2883	  Dominant	   0.9384	   0.9514	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   Genotype	   0.2351	   0.5182	  
rs62003625	   	   	  	   Additive	   0.3441	   0.4872	  Recessive	   0.4674	   0.4199	  Dominant	   0.2718	   0.8933	  Genotype	   0.4859	   0.6831	  
rs113629315	   	   	  	   Genotype	   0.2834	   0.7398	  	  	  
	  	  
 
 	  	  
